| Excerpt | Reference |
|---|
| "Twenty cases of endometrial carcinoma are reported, observed in women who had received long term tamoxifen treatment as adjuvant therapy for breast cancer." | ( Bobin, JY; Lasset, C; Mignotte, H; Rivoire, M; Saez, S; Sasco, AJ, 1992) |
| "Although localized endometrial cancer is effectively treated with surgery and radiation therapy, the treatment of advanced disease remains problematic." | ( Dvoretsky, P; Randall, ME; Spirtos, NM, 1995) |
| "Endometrial carcinoma is one of the commonest cancers of the female genital tract." | ( Bishai, N; el-Badawy, N; el-Maraghy, MA; Wafa, GA, 1994) |
| "Endometrial cancer is a disease with a major indication for surgical treatment." | ( López de la Osa González, E, 1994) |
| "Although endometrial carcinoma is the most common gynecological cancer, it only rarely metastasizes to the skin, with a reported prevalence of 0." | ( Bigler, LR; Gams, RA; Spencer, DM; Wilkin, JK, 1994) |
| "Endometrial carcinoma is associated with antecedent simple and complex hyperplasia, and the endometrium is a target tissue for the action of cytokines and growth factors." | ( Demopoulos, RI; Gold, LI; Goswami, S; Korc, M; Marmor, M; Mittal, KR; Nactigal, L; Saxena, B, 1994) |
| "The pathogenesis of endometrial cancer is known to be connected to estrogens." | ( Csermely, T; Keller, G; Környei, JL; Vértes, M, 1993) |
| "Endometrial carcinoma is the most common gynaecological malignancy." | ( Satyaswaroop, PG, 1993) |
| "The prognosis for endometrial cancer is correlated to the proliferative activity, expressed as the fraction of cells in the synthesis phase (S-phase fraction [SPF])." | ( Bäckström, T; Boman, K; Stendahl, U; Strang, P, 1993) |
| "Most recurrences of endometrial cancer are identified within 3 years of initial diagnosis." | ( Cohen, CJ; Rahaman, J, 1995) |
| "On the other hand, endometrial carcinoma is considered to be one of hormone dependent tumors." | ( Jobo, T; Kato, Y; Kuramoto, H; Sato, R; Tateoka, K, 1996) |
| "Endometrial carcinoma is one of the most common gynaecological cancers in Western countries." | ( Dieras, V; Paraiso, D; Pierga, JY; Pouillart, P, 1995) |
| "women endometrial cancer is the most common invasive gynecological cancer, it has a relatively favorable prognosis." | ( Schottenfeld, D, 1995) |
| "Endometrial cancer is the most common gynecologic malignancy seen in the United States." | ( Creasman, WT, 1997) |
| "Endometrial carcinoma is the commonest female genital tract malignancy in the south of Israel." | ( Bar-Dayan, A; Cohen, Y; Glezerman, M; Piura, B; Yanai-Inbar, I, 1997) |
| "Endometrial carcinomas are characterized by a relatively favorable prognosis with a 5-year survival of about 80%." | ( Bar-Dayan, A; Cohen, Y; Glezerman, M; Piura, B; Yanai-Inbar, I, 1997) |
| "Endometrial carcinoma is not commonly seen in India as in the West." | ( Jose, R; Kekre, AN; Seshadri, L, 1997) |
| "The incidence of endometrial cancer is increased in women who take tamoxifen." | ( Gelmann, EP; Stearns, V, 1998) |
| "Endometrial cancer is the most common pelvic genital cancer in women." | ( Grin, W; Grünberger, W, 1998) |
| "The two types of endometrial carcinomas are preceded by precancerous lesions." | ( Dubois, M; Foidart, JM; Gilliquet, A; Goffin, F; Kridelka, F; Nondonfaz, N, 1997) |
| "Endometrial cancer is the most common pelvic gynecologic cancer in women." | ( Ball, HG; Elkadry, EA, 1998) |
| "Some endometrial cancers are hormonally dependent." | ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Endometrial cancer is the fourth most common malignancy in women with an estimated 36,100 new cases diagnosed in the United States." | ( Baumann, P; Deppe, G; Munkarah, A, 2000) |
| "Endometrial cancer is the fourth most common female malignancy in women in developed countries." | ( Clements, JA; Myers, SA, 2001) |
| "The incidence of endometrial cancer is highest among relatively affluent Caucasians." | ( Southcott, BM, 2001) |
| "Endometrial carcinoma is the most common cancer of the female reproductive organs in the United States." | ( Akhmedkhanov, A; Toniolo, P; Zeleniuch-Jacquotte, A, 2001) |
| "Endometrioid endometrial carcinoma is caused by a combination of mutational events and hormonal factors." | ( Baak, JP; Fitzgerald, JT; Gentleman, R; Gray, R; Gullans, SR; Kust, GA; Mutter, GL; Neuberg, D; Wei, LJ; Wilcox, M, 2001) |
| "Endometrial cancer is characterized by alterations in the stromal cells and the supporting extracellular matrix in addition to the intrinsic alterations of the malignant epithelial cells." | ( Arnold, JT; Kaufman, DG; Lessey, BA; Seppälä, M, 2002) |
| "Endometrial cancer is usually diagnosed at an early stage where surgery alone is the adequate therapy." | ( Emons, G; Hinney, B; Huschmand, H; Krauss, T; Viereck, V, 2002) |
| "Endometrial carcinoma is a rare iatrogenic complication due to the adverse estrogenic like effect of Tamoxifen on the uterine mucosa." | ( Bailet, C; Hannoun-Lévi, JM; Largillier, R; Magné, N; Marcy, PY, 2001) |
| "Endometrial cancer is believed to have a better prognosis than cervical cancer." | ( Kanakura, Y; Kometani, K; Nakazawa, K; Niwa, K; Sekiya, T, 2002) |
| "Endometrial cancer is associated with endogenous and exogenous estrogen excess." | ( Hampton, JM; Kanarek, MS; McElroy, JA; Newcomb, PA; Remington, PL; Trentham-Dietz, A, 2002) |
| "Endometrial carcinoma is an increasing problem, and the value of a screening program is discussed." | ( Salvesen, HB, 2002) |
| "Endometrial cancer is a hormone-dependent disease and therefore an adjuvant hormonal therapy might improve the outcome in the early stages of the disease." | ( Brunnert, K; Kaufmann, M; Kreienberg, R; Loibl, S; Melchert, F; Mösch, R; Neises, M; Schermann, J; Seufert, R; Stiglmayer, R; Stosiek, U; von Minckwitz, G, 2002) |
| "Endometrial cancer is a disease of the affluent, developed world, where epidemiological studies have shown that > or =40% of its incidence can be attributed to excess body weight." | ( Kaaks, R; Kurzer, MS; Lukanova, A, 2002) |
| "Endometrial cancers are either associated with an hyperestrogenic or atrophic background." | ( Bergeron, C, 2002) |
| "But, their role in endometrial cancers is unknown." | ( Hellmich, MR; Levine, L; Licci, JA; Townsend, CM, 2003) |
| "The development of endometrial cancer is largely related to prolonged exposure to unopposed estrogens." | ( Canchola, AJ; Horn-Ross, PL; John, EM; Lee, MM; Stewart, SL, 2003) |
| "Endometrial carcinoma is a common malignancy of the genital tract." | ( Fujimoto, S; Nomura, E; Sugawara, T, 2004) |
| "Endometrial carcinoma is often listed in data sheets as an absolute contraindication to hormone replacement therapy." | ( Mueck, AO; Seeger, H, 2003) |
| "Endometrial carcinoma is listed under the absolute contraindications to hormone therapy (HT)." | ( Mueck, AO; Seeger, H, 2004) |
| "In North America, endometrial cancer is the most prevalent cancer of the female genital tract." | ( Bellone, S; Cannon, MJ; O'Brien, TJ; Pecorelli, S; Roman, JJ; Santin, AD, 2004) |
| "Estrogen-dependent endometrial cancer is related to unopposed and prolonged estrogen stimulation." | ( Adamski, J; Rizner, TL; Rupreht, R; Sinkovec, J; Smuc, T, 2006) |
| "Endometrial cancer is the most common malignancy of the female genital tract." | ( Penning, TM; Rizner, TL; Rupreht, R; Sinkovec, J; Smuc, T, 2006) |
| "Endometrial cancer is the most common gynecologic malignancy in the United States." | ( Chen, C; Modugno, F; Ness, RB; Weiss, NS, 2005) |
| "Endometrial cancer is the most common gynaecological cancer, and is associated with endometrial hyperplasia, unopposed oestrogen exposure and adjuvant therapy for breast cancer using selective oestrogen-receptor modulators (SERMs), particularly tamoxifen." | ( Shang, Y, 2006) |
| "Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases projected in the United States for 2006." | ( Hecht, JL; Mutter, GL, 2006) |
| "Endometrial cancer is the fourth most prominent cancer among all feminine cancers in the Western world." | ( Asselin, E; LeBlanc, K; Lemoine, P; Parent, S; Sexton, E; Van Themsche, C, 2006) |
| "Endometrial cancer is the most common invasive gynecologic malignancy but the molecular mechanisms underlying its onset and progression are poorly understood." | ( Bradford, AP; Haughian, JM; Jackson, TA; Koterwas, DM, 2006) |
| "Endometrial cancer is associated with both EGFR and HER2 receptor activation." | ( Deguchi, M; Kennedy, S; Kitao, K; Maruo, T; Ohara, N; Sugimoto, M; Takemura, N; Yoshida, S, 2007) |
| "Endometrial cancer is the most abundant female gynecologic malignancy, ranking fourth in incidence among invasive tumors in women." | ( Askerlund, A; Holmberg, E; Karlsson, S; Levan, KK, 2007) |
| "Endometrial carcinoma is one of the most common female pelvic malignancies." | ( Ito, K; Sasano, H; Utsunomiya, H; Yaegashi, N, 2007) |
| "Endometrial cancer is the most common type of gynecologic cancer in the United States." | ( Buttin, BM; Hardt, JL; Hoekstra, AV; Kim, JJ; Lurain, JR; Schink, JC; Singh, DK; Ward, EC, 2008) |
| "Endometrial cancer is one of the most common gynaecological cancers in western countries." | ( Koensgen, D; Mustea, A; Oskay-Ozcelik, G; Sehouli, J, 2008) |
| "Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States." | ( Arterburn, JB; Dai, D; Hathaway, HJ; Nayak, TK; Norenberg, JP; Prossnitz, ER; Ramesh, C; Sklar, LA, 2008) |
| "Endometrial carcinoma is divided into endometrioid and papillary serous type carcinoma according to the histological characteristics and regarding to the unopposed estrogenic stimulation." | ( Ahn, HJ; Bae, J; Kim, SJ; Ko, JE; Lee, S; Sakuragi, N; Yoon, S, 2008) |
| "Endometrial cancer is the most common malignant tumor of the female genital tract in the developed world." | ( Emons, G; Gründker, C; Günthert, AR, 2008) |
| "Endometrial cancer is related to estrogen stimulation not opposed by progesterone." | ( Rizner, TL; Smuc, T, 2009) |
| "Endometrial cancer is the most common type of gynecologic cancer in the United States." | ( Berry, E; Clardy, J; Hardt, JL; Kim, JJ; Lurain, JR, 2009) |
| "Canine endometrial carcinomas are rare, and mostly occur in geriatric bitches." | ( Palmeira, C; Payan-Carreira, R; Pires, MA; Seixas, F, 2010) |
| "Endometrial cancer is the most common gynecologic malignancy in the Western world and is strongly associated with obesity." | ( Arriba, LN; Fader, AN; Frasure, HE; von Gruenigen, VE, 2009) |
| "Endometrial cancer is the third most common cancer in women and broad screening for DACH1 expression will further our understanding of this disease." | ( Cheng, L; Jiang, J; Kong, B; Lisanti, MP; Lü, Q; Nan, F; Pestell, RG; Popov, VM; Wang, C; Wei, S; Zhou, J, 2009) |
| "Endometrial carcinoma is the most common neoplasm of the female genital tract, accounting for nearly one half of all gynecologic cancers in the Western world." | ( Choi, KC; Leung, PC; MacCalman, CD; Park, DW, 2009) |
| "Uterine endometrial cancer is the most common gynecologic malignancy, and benign endometrial hyperplasia or polyps should be differentiated from endometrial cancer." | ( Matsuzaki, K; Nishitani, H; Takeuchi, M, 2009) |
| "Endometrial cancer is the most common gynaecological malignancy; risk factors include exposure to oestrogens and high body mass index." | ( Anderson, RA; Bombail, V; Brown, P; Collins, F; Jabbour, HN; MacPherson, S; Saunders, PT; Williams, AR, 2009) |
| "Endometrial cancer is one of the most common gynecologic malignancies and its incidence has recently increased." | ( Liang, XW; Lin, SL; Qiao, J; Schatten, H; Sun, QY; Wang, ZB; Wang, ZY; Yan, LY, 2009) |
| "Endometrial carcinoma is a malignant tumor in the uterus." | ( Hao, Q; Hu, YL; Liang, YJ; Wang, JD; Wang, QL; Wu, YZ, 2009) |
| "Endometrial carcinoma is a relatively common condition which may occur with more than 6,400 new cases diagnosed each year in the UK (Cancer Research UK Statistics http://info." | ( Grimes, C; Lalude, O, 2010) |
| "Endometrial cancer is one of the most frequently diagnosed cancer in females with prevalence of 22 in 100,000 women." | ( Miltyk, W; Pałka, JA; Surazyński, A; Sławomir, W, 2009) |
| "We conclude that endometrial carcinoma is characterized by profound changes in sphingolipid metabolism that likely contribute to its progression and chemoresistance." | ( Baranowski, M; Błachnio-Zabielska, AU; Górski, J; Knapp, M; Knapp, P; Zabielski, P, 2010) |
| "Endometrial cancer is the most common gynecological malignancy." | ( Audet-Walsh, E; Ayotte, P; Bélanger, A; Brisson, J; Caron, P; Grégoire, J; Guillemette, C; Lépine, J; Ménard, V; Plante, M; Têtu, B; Villeneuve, L, 2010) |
| "Endometrial carcinoma is a common malignancy of the female genital tract." | ( Baloglu, A; Bezircioglu, I; Cetinkaya, B; Hicyilmaz, L, 2010) |
| "Endometrial cancer is a cancer of the lining of the womb and worldwide is the seventh most common cancer in women." | ( Brockbank, E; Bryant, A; Gallagher, C; Kokka, F; Oram, D, 2010) |
| "Although endometrial cancer is a common invasive gynecologic malignancy, the involvement of uterine CaBP-28k in apoptotic signaling of endometrial cancer is poorly understood." | ( Choi, KC; Jeung, EB; Jung, EM, 2011) |
| "Type I and II endometrial cancer are biologically and clinically distinct, with type II cancers having a high frequency of p53 mutations and an association with chromosomal instability." | ( Anderson, KE; Cerhan, JR; Mariani, A; Robien, K; Uccella, S; Vierkant, RA; Wang, AH, 2011) |
| "Endometrial cancer is one of the most common gynecologic malignancies and many factors influence in its growth and development." | ( Izumi, K; Ogawa, H; Takahashi, T; Uehara, H, 2011) |
| "Endometrial cancer is the most common gynecologic cancer and its incidence is rising among premenopausal women." | ( Shah, MM; Wright, JD, 2011) |
| "Endometrial cancer is the most common gynaecological cancer in the western world, the incidence increasing in the United Kingdom by over 40% since 1993." | ( Blann, A; Evans, T; Ganesan, R; Pearmain, P; Sany, O; Sundar, S, 2011) |
| "Endometrial cancer is the most commonly diagnosed female genital tract malignancy." | ( Burnett, AF; Friedman, TM; Godley, AL; Heard, ME; Pabona, JM; Simmen, FA; Simmen, RC; Simmons, CD; Spataro, MT, 2011) |
| "Endometrial cancer is among the three most common cancers in females in industrialized countries." | ( Abal, M; Alonso-Alconada, L; Alonso-Nocelo, M; Anido, U; Barbazan, J; Bouso, M; Colas, E; Cueva, J; Curiel, T; Forteza, J; Gil-Moreno, A; Lopez-Lopez, R; Muinelo-Romay, L; Reventos, J, 2011) |
| "Endometrial cancer is the most common genital tract carcinoma among women in developed countries, with most women presenting with stage 1 disease." | ( Bryant, A; Keep, SL; Kitchener, HC; Lilford, R; Martin-Hirsch, PP, 2011) |
| "Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades." | ( De Geest, K; Leslie, KK; Thiel, KW; Yang, S, 2011) |
| "Endometrial cancer is the most common gynecologic malignancy." | ( Blank, SV; Curtin, JP; Czok, S; Korets, SB; Schneider, RJ, 2011) |
| "Endometrial cancer is one of the most common gynecological malignancies in Japan, where the disease shows an increasing morbidity." | ( Hattori, M; Hongo, A; Miyake, Y; Miyamoto, T; Mori, M; Nakaizumi, A; Ohno, E; Ohno, S; Sakaguchi, T; Ueda, M; Yakushiji, H, 2012) |
| "While early-stage endometrial cancer is often successfully treated with surgical intervention, treatment of advanced endometrial carcinoma can be difficult and prognosis poor, particularly in the context of metastatic or recurrent disease." | ( Dizon, DS; Hill, EK, 2012) |
| "Endometrial cancer is associated with numeric and structural chromosomal abnormalities, microsatellite instability (MSI), and alterations that activate oncogenes and inactivate tumor suppressor genes." | ( Clayton, AC; Distad, TJ; Halling, KC; Kerr, SE; Kipp, BR; Medeiros, F; Peterson, LM; Smith, DI, 2012) |
| "Endometrial cancer is one of the most frequently diagnosed malignant neoplasms among women." | ( Horzelski, T; Lange, D; Nowak, L; Olejek, A; Olszak-Wasik, K; Zamłyński, J, 2012) |
| "Endometrial carcinoma is the common malignant tumor of the female genital tract, and its incidence is increasing." | ( Fang, S; Huang, H; Shu, J; Teichman, PG; Xing, L, 2012) |
| "Endometrial cancer is associated with metabolic disturbances related to its underlying risk factors, including obesity and diabetes." | ( Bain, JR; Brinton, LA; Falk, RT; Garcia-Closas, M; Gaudet, MM; Gunter, MJ; Lissowska, J; Newgard, CB; Peplonska, B; Pfeiffer, RM; Potischman, N; Sherman, ME; Stevens, RD, 2012) |
| "Endometrial carcinoma is the most common gynecologic cancer, yet the mechanisms underlying this disease process are poorly understood." | ( Bender, D; DeGeest, K; Engelhardt, JF; Fornalik, H; Goodheart, MJ; Liu, X; Meyerholz, DK; Neff, T; Park, SY; Shelton, DN; Xie, W, 2012) |
| "Endometrial cancer is a major problem for women but only a small number of comprehensively characterized cell models are available for studies." | ( Chen, R; Hu, Q; Liao, Q; Xie, Y; Yu, L; Zhang, Y, 2012) |
| "Endometrial carcinoma is one of the most common malignancies in the female genital tract, usually treated by surgery and radiotherapy." | ( Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A, 2012) |
| "Endometrial carcinoma is one of the most common female tract genital malignant tumors." | ( Bao, XX; Li, Q; Li, XP; Wang, JL; Wei, LH; Xie, BS, 2012) |
| "Endometrial cancer is the most common malignancy of the female genital tract, and the incidence and mortality rates from this disease are increasing." | ( Burton, E; Fligelman, T; Griffith, JK; Lin, CY; Pollard, JW; Qualls, CR; Smith, HO; Stephens, ND; Wang, T, 2013) |
| "Endometrial cancer is a hormone-driven cancer, with approximately 80% of endometrial cancers arising attributable to either an excess of estrogen or a lack of progesterone." | ( Carlson, MJ; Leslie, KK; Thiel, KW; Yang, S, 2012) |
| "Endometrial cancer is the fourth most common female cancer in the UK and the most common gynaecological cancer." | ( Braybrooke, J; Edey, K; Manley, K; Murdoch, J, 2012) |
| "The risk of endometrial cancer is higher in BRCA1 mutation carriers than in the general population." | ( Foulkes, WD; Ghadirian, P; Gronwald, J; Iqbal, J; Karlan, B; Kim-Sing, C; Lubinski, J; Lynch, HT; Moller, P; Narod, SA; Neuhausen, SL; Ping, S; Rosen, B; Segev, Y; Senter, L; Singer, CF; Tung, N, 2013) |
| "Endometrial cancer is common in western women, and the rates are very high; however in India, the rates are as low as 4." | ( Balasubramaniam, G; Mahantshetty, U; Rasika, B; Sushama, S, 2013) |
| "Endometrial cancer is preceded by endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations, but the precise causes of endometrial cancer remain uncertain." | ( Behringer, RR; Broaddus, RR; Cho, SN; Jeong, JW; Kim, TH; Ku, BJ; Lee, DK; Lydon, JP; McCampbell, AS; Orvis, GD, 2013) |
| "Endometrial cancer is the most common gynecological malignancy in the developed World." | ( Rižner, TL, 2013) |
| "Endometrial cancer is the most commonly diagnosed gynecologic malignancy worldwide; yet the tumor microenvironment, especially the fibroblast cells surrounding the cancer cells, is poorly understood." | ( Chung, I; Mat Adenan, NA; Mohamed, Z; Subramaniam, KS; Tham, ST; Woo, YL, 2013) |
| "Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity contributing to approximately 8,200 annual deaths in the USA." | ( Bulun, SE; Chakravarti, D; Coon, JS; Dyson, MT; Kim, JJ; Ma, JJ; Malpani, S; Monsivais, D; Ono, M; Pavone, ME; Xin, H; Zhao, H, 2013) |
| "Endometrial cancer is the most frequent malignancy of the female reproductive system, while cutaneous metastasis is extremely rare in endometrial cancer." | ( Liu, GY; Ma, XG; Qi, Z; Sheng, HN; Tian, WY; Wang, YM; Xue, FX, 2013) |
| "Endometrial cancer is the most common malignancy of women in developed countries, and its incidence is rising among pre- and postmenopausal women." | ( Ali, AT, 2013) |
| "Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer." | ( Kiyokawa, T; Mitsuhashi, A; Sato, Y; Shozu, M, 2014) |
| "Endometrial cancer is the most common gynecological cancer in the Western world." | ( Anwar, S; Barthakur, U; El-Modir, A; Fernando, I; Tirmazy, SH, 2014) |
| "Loss of PR in endometrial cancer is associated with increased proliferation, poor survival, and increases from primary to metastatic lesions." | ( Berg, A; Halle, MK; Hoivik, EA; Krakstad, C; Kusonmano, K; Mills, GB; Salvesen, HB; Tangen, IL; Trovik, J; Werner, HM, 2014) |
| "Endometrial cancer is the most common gynecologic malignancy." | ( Bearss, J; Gajiwala, S; Janat-Amsbury, M; Sharma, S; Sorna, V; Theisen, ER, 2014) |
| "Endometrial cancer is the most frequently diagnosed gynecological malignancy." | ( Adamski, J; Anko, M; Rižner, TL; Sinreih, M; Zukunft, S, 2015) |
| "Endometrial cancer is a common malignancy of the female genital tract." | ( Chang, CC; Houng, JY; Hsu, HF; Huang, KH; Kuo, SM; Ling, XH; Wu, JM, 2014) |
| "In France, endometrial cancer is at the first rank of gynecological cancers for cancer incidence, before ovarian and cervical cancers." | ( Buecher, B; Cottereau, E; Dagousset, I; de Pauw, A; Elan, C; Fourchotte, V; Gauthier-Villars, M; Lae, M; Sénéchal, C; Stoppa-Lyonnet, D, 2015) |
| "Endometrial cancer is the most common gynecologic malignancy in women worldwide." | ( Choi, KC; Kim, SU; Yi, BR, 2015) |
| "Endometrial cancer is the most common female reproductive cancer in the United States and is associated with deregulated tight junction protein expression." | ( Cuevas, ME; Gaska, JM; Gist, AC; King, JM; Sheller, RA; Todd, MC, 2015) |
| "Endometrial cancer is the most prevalent gynecologic cancer in the Western world, and the number of advanced chemotherapy-resistant cancers is increasing with the absolute increase in patients." | ( Hayashi, M; Ohmichi, M; Ono, YJ; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y, 2015) |
| "Endometrial carcinoma is the most common gynecological malignancy among women worldwide." | ( Liu, C; Ran, X; Xiao, L; Yang, J; Zhang, K; Zhou, P, 2015) |
| "Endometrial carcinoma is the most common gynecologic malignancy is the United States and accounts for 6% of all cancers in women." | ( Bhusari, S; Dunnick, J; Elmore, S; Harvey, JB; Hoenerhoff, MJ; Hong, HH; Masinde, T; Osborne, TS; Pandiri, AR; Peddada, S; Ton, TV, 2015) |
| "Endometrial cancer is the most common malignancy of the female genital tract in developed countries and second to cervical cancer in India." | ( Arora, A; Suri, V, 2015) |
| "Endometrial cancer is the most common gynecologic malignancy and the fourth most common malignancy in women." | ( Aloisio, GM; Amelio, AL; Brekken, RA; Castrillon, DH; Cuevas, I; DeBerardinis, RJ; Lea, JS; Miller, DS; Nakada, Y; Peña, CG; Saatcioglu, HD; Wong, KK; Zhang, S, 2015) |
| "Endometrial carcinoma is the most common gynecological cancer and its treatment is still controversial, especially in its early stages." | ( Abdelazim, IA; Allam, IS; El-Kady, OS; Farghali, MM; Gareer, WY; Rashed, AR; Sweed, MS, 2015) |
| "Endometrial cancer is one of the most common gynecologic malignancies." | ( Bai, X; Bi, X; Cheng, L; Li, F; Liu, S; Pan, J; Zhang, X; Zhao, AZ, 2015) |
| "Endometrial cancer is the most frequent cancer occurring in the female genital tract in the Western countries." | ( Cho, A; Kang, WJ; Kim, HJ; Kim, YT; Yun, M, 2016) |
| "Most patients with endometrial cancer are diagnosed early, when cancer is confined to the uterus." | ( Roett, MA, 2015) |
| "Type I endometrial cancer is a common tumor of the female genital tract." | ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016) |
| "Endometrial cancer is a hormonally responsive malignancy." | ( Behbakht, K; Guy, MS; Post, MD; Qamar, L; Sartorius, CA; Sheeder, J; Spillman, MA, 2016) |
| "Endometrial cancer is one of the main cancers occurring in industrialized countries." | ( Parahuleva, P; Uchikov, P; Uchikova, E, 2015) |
| "Although endometrial cancer is clearly influenced by hormonal factors, few epidemiologic studies have investigated the role of endogenous estrogens or especially estrogen metabolites." | ( Anderson, GL; Brinton, LA; Falk, RT; Felix, AS; Fuhrman, BJ; Gass, ML; Kuller, LH; Pfeiffer, RM; Rohan, TE; Strickler, HD; Trabert, B; Wentzensen, N; Xu, X, 2016) |
| "Endometrial cancer is the most common gynecological malignancy among females worldwide, approximately 320,000 women being diagnosed with the disease each year and 76,000 dying." | ( Jalil, NA; Othman, NH; Siti-Azrin, AH; Wan-Nor-Asyikeen, WA; Zain, AA, 2016) |
| "Endometrial carcinoma is one of the most common malignancies of the female reproductive system, but the aetiology and pathogenesis are not well understood, although adipokines such as visfatin may be involved." | ( Gao, C; Gao, J; Teng, F; Tian, W; Wang, Y; Xue, F; Yan, Y; Yang, W; Zhang, Y, 2016) |
| "Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries." | ( Bogliolo, S; Cassani, C; Dominoni, M; Ferrero, S; Gardella, B; Iacobone, AD; Orlandini, A; Spinillo, A; Venturini, PL; Viazzo, F, 2017) |
| "Endometrial cancer is the most common cancer in women, typically with onset after menopause." | ( Chen, HY; Hsia, SM; Huang, TC; Lin, LC; Shieh, TM; Wang, CW; Wang, KL; Wu, CH, 2016) |
| "The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy." | ( de Waal, YR; Leenders, W; Ottevanger, PB; Tops, B; van der Steen, MJ; Westermann, A, 2016) |
| "Endometrial carcinoma is the most common gynecologic cancer in developed nations, and the annual incidence is projected to increase, secondary to the high prevalence of obesity, a strong endometrial carcinoma risk factor." | ( Bell, DW; Felix, AS; Sherman, ME; Yang, HP, 2017) |
| "Endometrial cancer is the most common, and second most lethal, gynecological malignancy, and its rates of incidence and death are growing." | ( Cheng, JC; Klausen, C; Leung, PCK; Xiong, S, 2017) |
| "Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion." | ( Guerra, ENS; Lofrano-Porto, A; Meireles, CG; Pereira, SA; Rêgo, DF; Simeoni, LA; Valadares, LP, 2017) |
| "Endometrial cancer is the most common malignancy of the female genital tract." | ( Broaddus, RR; Jeong, JW; Kim, BG; Kim, TH; Lee, JH; Lim, JM; Yang, WS; Yoo, JY, 2018) |
| "Endometrial carcinoma is the most common malignancy of the female genital tract and is the fourth most common malignancy among women worldwide." | ( Deng, X; Hou, C; Liang, T; Wang, H; Zhu, L, 2017) |
| "Endometrial cancer is the most common gynecologic cancer in the United States and its incidence and mortality has been rising over the past decade." | ( Dellinger, TH; Finlay, J; Glackin, CA; Han, ES; Lowe, G; Roberts, CM; Wen, W, 2017) |
| "Endometrial cancer is a common cause of death in gynecological malignancies." | ( Ding, N; Ding, Y; Liu, P; Su, S; Tang, Y; Wang, Q; Yu, X; Zhang, H, 2018) |
| "Endometrial cancer is one of the most commonly diagnosed cancers in women." | ( Buszewski, B; Cendrowski, K; Gadzała-Kopciuch, R; Kowalkowski, T; Pajewska, M; Sawicki, W; Łojko, M, 2018) |
| "Endometrial cancer is the most prevalent genital tract cancer in occident and the third most common cancer among women in Tunisia." | ( Amel, M; Boujelbene, N; Charfi, L; Doghri, R; Driss, M; Gabsi, A; Mrad, K; Yahyaoui, Y, 2018) |
| "Endometrium cancer is the most common invasive gynecologic malignancy in developed countries." | ( Cakmakoglu, B; Catmakas, T; Iplik, ES, 2018) |
| "Diagnosis of endometrial cancer is primarily based on symptoms and imaging, with early-stage disease being difficult to diagnose." | ( Chen, W; Lash, GE; Liu, Y; Qian, Y; Shi, K; Su, Y; Wang, Q; Xuan, X, 2018) |
| "Endometrial cancer is increasingly prevalent in western societies and affects mainly postmenopausal women; notably incidence rates have been rising by 1." | ( Alavanos, A; Andreatos, N; Angelou, A; Antoniou, EA; Apostolou, KG; Athanasiou, A; Damaskos, C; Damaskou, Z; Daskalopoulou, A; Diamantis, E; Dimitroulis, D; Garmpi, A; Garmpis, N; Kalampokas, E; Kalampokas, T; Kontzoglou, K; Kostakis, A; Lavaris, A; Mantas, D; Margonis, GA; Markatos, K; Moschos, MM; Nikiteas, N; Nonni, A; Perrea, D; Sampani, A; Schizas, D; Spartalis, E; Spartalis, M; Tsivelekas, K; Tsourouflis, G; Valsami, S, 2018) |
| "Endometrial carcinoma is the primary cancer type in the female genital system." | ( Bulgurcuoglu Kuran, S; Cakmakoglu, B; Ergen, A; Gulec Yilmaz, S; Iplik, ES; Isbir, T; Iyibozkurt, AC; Koc, A; Timirci Kahraman, O, 2018) |
| "Endometrial cancer is one of the most common gynaecological cancers in developed countries." | ( Conforti, F; Crosbie, EJ; Eldakhakhny, S; Melino, G; Sayan, BS; Zhou, Q, 2018) |
| "Uterine endometrial carcinoma is one of the common cancers in females." | ( Asano, T; Hashimoto, S; Hirohashi, Y; Ikeo, K; Kanaseki, T; Kawai, N; Kubo, T; Kuroda, T; Mariya, T; Mizuuchi, M; Murai, A; Nakatsugawa, M; Saito, T; Tabuchi, Y; Torigoe, T; Tsukahara, T; Uno, S, 2019) |
| "Endometrial carcinoma is one of the most common malignancies in the female reproductive system." | ( Cai, T; Chen, H; Chen, R; Jiang, Q; Lin, W; Liu, S; Liu, W; Peng, J; Sheng, X; Wang, F; Xiong, H; Xu, X; Zhang, M; Zheng, W, 2018) |
| "Endometrial cancer is one of the most common gynecological malignancies and has exhibited an increasing incidence rate in recent years." | ( Ju, DD; Li, J; Lu, H; Song, WW; Wang, JH; Yang, GD; Yang, XM; Zhang, CC; Zhang, R; Zhang, ZG; Zhu, LY, 2019) |
| "Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year." | ( Blanchard, Z; Gertz, J; Maurer, KA; Rodriguez, AC, 2019) |
| "Endometrial cancers are associated with several critical gene mutations, including PIK3A, PTEN, and KRAS." | ( Cacalano, N; Jin, S; Kamrava, M; Konecny, G; Liu, Q; Wang, S; Xie, M; Zhang, H; Zhu, H, 2019) |
| "Endometrial cancer is a surgically staged cancer." | ( Fung Kee Fung, M; Le, T; McDonald, S; Samant, R, 2019) |
| "SLN assessment in endometrial cancer is feasible and safe with high NPV (99%)." | ( Backes, FJ; Cohen, D; Cohn, DE; Fanning, E; Fowler, JM; O'Malley, DM; Salani, R; Suarez, AA, 2019) |
| "Endometrial cancer is the most common gynecological cancer in the United States." | ( Bateman, NW; Casablanca, Y; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Loffredo, J; Lokshin, A; Maxwell, GL; Tarney, CM; Tian, C; Wang, G; Zhou, M, 2019) |
| "Endometrial cancer is the most common cancer of the female reproductive system in the developed countries." | ( Li, F; Li, L; Li, N; Li, T; Liu, M; Qin, X; Xue, J, 2019) |
| "Endometrial carcinoma is the most commonly encountered gynecological cancer in women worldwide and is also one of the popular models of the hormone-dependent carcinomas." | ( Dogan, S; Erdogan, G; Erkaymaz, T; Sik, B; Simsek, T; Tongur, T; Unal, B, 2019) |
| "Endometrial cancer is the fifth leading cancer among women." | ( Asemi, Z; Chaichian, S; Chamani, M; Dana, PM; Moazzami, B; Mobini, M; Sadoughi, F; Shafabakhsh, R, 2020) |
| "Uterine endometrial cancer is associated with poor survival outcomes in patients with advanced-stage disease." | ( Enomoto, T; Ishiguro, T; Minamino, T; Mori, Y; Ohata, H; Okamoto, K; Sato, A; Ueda, H; Yamawaki, K; Yoshida, Y; Yoshihara, K, 2019) |
| "Endometrial cancer is a common gynaeological malignancy: life time exposure to oestrogen is a key risk factor." | ( Collins, F; Esnal-Zufiaurre, A; Fitzgerald, C; Gibson, DA; Itani, N; Saunders, PTK, 2020) |
| "Endometrial cancer is the most common gynecologic malignancy in developed countries." | ( Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Perrone, E; Ratner, E; Santin, AD; Scambia, G; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B, 2020) |
| "Endometrial carcinoma is a type of gynecological cancer that originates in the endometrial epithelial tissue." | ( Chen, S; Li, W; Yao, L, 2020) |
| "Endometrial cancer is the most common malignancy of the female genital tract." | ( Arjona, Á; Barrios, P; Cascales-Campos, PA; Gil-Martínez, J; Manzanedo, I; Martínez-Regueira, F; Muñoz-Casares, C; Navarro-Barrios, Á; Pereira, F; Ramos-Bernardo, I; Torres-Melero, J, 2020) |
| "Endometrial cancer is the most commonly diagnosed gynecological malignancy in developing countries, and the second malignancy after cervical cancer in developing countries." | ( Aragona, A; Crespe, M; Depietri, V; Rodriguez, Y; Soderini, A, 2020) |
| "Endometrial cancer is the most common type of cancer in the female reproductive system." | ( Ayan, İÇ; Canbaz, HT; Cüce, G; Dursun, HG; Gültekin, B; Kalkan, SS; Keskin, İ; Kuzu, B; Şahin, Z, 2021) |
| "Endometrial cancer is the most common malignant tumor of female genital system worldwide." | ( Chen, L; Kong, C; Li, Y; Xue, P; Zhu, Z, 2021) |
| "Type I endometrial cancer is the most common gynaecological tumour in developed countries and its incidence is increasing also because of population aging." | ( Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A, 2021) |
| "Endometrial cancer is one of the most frequently diagnosed gynecological malignancies worldwide." | ( Hara, A; Inoue, F; Kukita, A; Osuga, Y; Sone, K; Taguchi, A; Takahashi, Y; Tanikawa, M; Toyohara, Y; Tsuruga, T, 2021) |
| "Endometrial carcinoma is one of the most common malignancies in the female reproductive system." | ( Chen, G; Li, Y; Liu, X; Shi, Y; Tang, Z; Wang, J; Wang, X; Wei, Z; Xue, C; Yu, H; Zhang, D; Zhang, L; Zhou, H, 2021) |
| "Endometrial cancer is the fifth most common cancer in women and atypical endometrial hyperplasia is a precancerous lesion." | ( Contreras-Perez, NA; Fernandez-Montoli, ME; Sabadell, J, 2021) |
| "Endometrial cancer is rare in women with LNG-IUS as only seven cases have been published in the literature." | ( Collins, D; Hanna, L; Steshenko, A, 2021) |
| "SLN assessment in endometrial cancer is feasible and safe with high sensitivity and high NPV when ICG and CNPs are combined and in low-risk patients." | ( Chen, J; Li, X; Li, Y; Liang, S; Liang, X; Sun, X; Wang, J; Wang, Z; Yang, X; Zhou, R, 2021) |
| "Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy." | ( Agnoli, C; Allen, N; Amiano, P; Biessy, C; Christakoudi, S; Colorado-Yohar, SM; Crous-Bou, M; Dimou, N; Dossus, L; Fortner, R; Gram, IT; Gunter, MJ; Gurrea, AB; Heath, AK; Kaaks, R; Keun, HC; Kouloura, E; Lécuyer, L; Mattiello, A; Merritt, MA; Nøst, TH; Palli, D; Rinaldi, S; Rothwell, JA; Sacerdote, C; Sánchez, MJ; Schmidt, JA; Schulze, MB; Severi, G; Siskos, AP; Travis, RC; Tsilidis, KK; Tumino, R; Vermeulen, R; Viallon, V; Weiderpass, E, 2021) |
| "Endometrial cancer is one of the most common types of cancer." | ( Esen, MA; Karaboğa Arslan, AK; Paşayeva, L; Tugay, O, 2022) |
| "Endometrial cancer is the most common malignancy of the female genital tract." | ( George, M; Kalantaridou, S; Papadimitriou, S; Paschopoulos, M; Tsonis, O; Zisi, M; Zygouris, D, 2022) |
| "Endometrial cancer is the most common gynecological cancer worldwide." | ( Huang, SM; Wang, YC; Wu, ZS, 2021) |
| "Endometrial carcinoma is the second most common gynecological malignancy." | ( Baumann, L; Gahlawat, AW; Hauke, J; Nees, J; Okun, JG; Schuhn, A; Tobar, TW, 2022) |
| "Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors." | ( Abdeddaim, C; Arnaud, A; Augereau, P; Bazan, F; Chakiba, C; Chevalier-Place, A; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, P; Joly, F; Lancry-Lecomte, L; Marcel, V; Pautier, P; Pérol, D; Ray-Coquard, I; Treilleux, I; You, B, 2022) |
| "Endometrial cancer is the most common gynecological cancer in developed countries." | ( Al Hennawi, K; Erdem Kış, E; Tiftik, RN; Ün, İ, 2022) |
| "Endometrial cancer is the most common malignancy of the female genital tract." | ( Jakiel, G; Janicka-Kośnik, M; Lukaszuk, A; Słabuszewska-Jóźwiak, A; Wdowiak, A, 2022) |
| "Endometrial carcinoma is one of the two cancers with rising mortality and morbidity in recent years." | ( Jiao, W; Lin, Z; Sui, X; Wang, Y; Zhao, J, 2022) |
| "Rare endometrial cancers are high-grade, aggressive malignancies which are often diagnosed at an advanced stage, and account for disproportionately more deaths than their more common low-grade counterparts." | ( Crane, E, 2022) |
| "Most endometrial cancers are estrogen receptor and progesterone receptor positive." | ( Kailasam, A; Langstraat, C, 2022) |
| "Most endometrial cancers are estrogen receptor and progesterone receptor positive." | ( Kailasam, A; Langstraat, C, 2022) |
| "Most endometrial cancers are estrogen receptor and progesterone receptor positive." | ( Kailasam, A; Langstraat, C, 2022) |
| "Endometrial cancer is the most common gynecological disease in developed countries." | ( Bogani, G; Cuccu, I; Di Dio, C; Di Donato, V; Lorusso, D; Musacchio, L; Muzii, L; Scambia, G, 2023) |
| "Endometrial cancer is the most common gynecological disease in developed countries." | ( Bogani, G; Cuccu, I; Di Dio, C; Di Donato, V; Lorusso, D; Musacchio, L; Muzii, L; Scambia, G, 2023) |
| "Black patients with endometrial cancer are less likely to express distress and receive referrals for support services compared to White patients." | ( Davidson, BA; Falkovic, M; Fish, LJ; Malone, S; Montes de Oca, MK; Reid, HW; Selvan, B; Wheeler, S, 2023) |
| "Black patients with endometrial cancer are less likely to express distress and receive referrals for support services compared to White patients." | ( Davidson, BA; Falkovic, M; Fish, LJ; Malone, S; Montes de Oca, MK; Reid, HW; Selvan, B; Wheeler, S, 2023) |
| "Endometrial cancer is a common gynecological malignancy." | ( Guo, K; Jiang, J; Liu, Y; Ma, X; Qiu, C; Sun, R; Wei, L; Xia, M, 2022) |
| "Endometrial cancer is the most common gynecological malignancy, affecting up to 3% of women at some point during their lifetime (Morice et al." | ( Chen, L; Jin, Y; Lai, Y; Pan, R; Wang, X; Xu, S; Xu, X; Yu, Y; Zhang, L; Zhang, T, 2023) |
| "Endometrial cancer is known to be an estrogen-dependent cancer, and it is believed that exposure to estrogens increases the risk of developing endometrial cancer in the absence of progesterone." | ( Bai, X; Ge, Z; Li, J; Li, L; Li, Z; Qi, R; Yang, H; Zhao, H; Zhou, M, 2023) |
| "Endometrial cancer is a hormone-dependent malignancy, and sex steroid hormones play a crucial role in its pathogenesis." | ( Thakur, L; Thakur, S, 2023) |
| "Endometrial carcinoma is the most common gynecological tumor in developed countries." | ( Ji, Y; Liu, M; Ma, C; Qu, P; Yu, D; Zhang, W; Zhao, J, 2023) |
| "Endometrial cancer is the most common gynecologic cancer and one of the only cancers for which incidence and mortality is steadily increasing." | ( Bae-Jump, VL; Buckingham, L; Deng, B; Fan, Y; Hao, T; John, C; O'Donnell, J; Secord, AA; Shen, X; Sun, W; Suo, H; Zhang, X; Zhao, Z; Zhou, C, 2023) |
| "Endometrial cancer is a very common and highly lethal reproductive malignant tumour in women." | ( Jiang, J; Mao, P; Wang, J; Wang, X; Zhang, C; Zhu, Y, 2023) |
| "Endometrial carcinoma is the most common malignancy of the genital tract in females in the United States, and it is one of the few human cancers increasing in incidence and mortality." | ( Ellenson, LH, 2023) |
| "However, data on endometrial cancers are limited." | ( Ahtikoski, A; Karihtala, P; Kuusiniemi, E; Puistola, U; Urpilainen, E, 2023) |
| Excerpt | Reference |
|---|
| "Twenty cases of endometrial carcinoma are reported, observed in women who had received long term tamoxifen treatment as adjuvant therapy for breast cancer." | ( Bobin, JY; Lasset, C; Mignotte, H; Rivoire, M; Saez, S; Sasco, AJ, 1992) |
| "A history of endometrial cancer has long been considered a contraindication to estrogen replacement therapy." | ( Creasman, WT, 1992) |
| "The authors describe three new cases of endometrial carcinoma developing in breast cancer patients taking tamoxifen and stress the necessity of carefully monitoring the uterine cavity under tamoxifen treatment." | ( Bardazzi, N; Citernesi, A; Curiel, P; Fontanarosa, M; Spinelli, G, 1991) |
| "90 patients with endometrial carcinoma treated from 1958 to 1984 by radiotherapy alone are presented." | ( Sun, JH, 1991) |
| "Both developed endometrial cancer after continuous treatment with tamoxifen for several years." | ( Nielsen, KM; Rasmussen, KL, 1991) |
| "MPA treatment of endometrial carcinoma reduces the sulfatide carbohydrate on the carcinoma cell surface and may be clinically more effective in reducing cell binding to laminin." | ( Isojima, S; Kawakita, M; Koyama, K; Nakata, Y; Ogasawara, T; Takemura, T; Tsuji, Y, 1995) |
| "Although localized endometrial cancer is effectively treated with surgery and radiation therapy, the treatment of advanced disease remains problematic." | ( Dvoretsky, P; Randall, ME; Spirtos, NM, 1995) |
| "Thirty patients with advanced/recurrent endometrial carcinoma were assigned to chemotherapy treatment at 4-week intervals with methotrexate 30 mg/m2 i." | ( Cha, SS; Ebbert, LP; Krook, JE; Langdon, RM; Long, HJ; Pfeifle, DM; Roshon, SG; Tschetter, LK; Veeder, MH, 1995) |
| "Subsequent standard treatment of endometrial cancer by abdominal hysterectomy and bilateral salpingo-oophorectomy after 4 weeks revealed no clinical or histological evidence of persistent carcinoma." | ( Hepp, H; Kimmig, R; Korell, M; Kürzl, R; Müller-Höcker, J; Strowitzki, T, 1995) |
| "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy." | ( Eddy, GL; Folk, JJ; Mazur, MT; Musa, AG, 1995) |
| "Two cases of recurrent uterine endometrial cancer treated earlier with MPA were presently treated with an addition of etoposide." | ( Fujita, H; Ishizaki, T; Itoh, R; Okada, H; Yamamoto, T; Yasuda, J, 1995) |
| "Two women with endometrial cancer and precancerous lesion treated with medroxyprogesterone are presented." | ( Kedzia, H; Warenik-Szymankiewicz, A; Wolna, M, 1994) |
| "Progress in the treatment of advanced endometrial cancer and uterine sarcomas is beginning." | ( Kavanagh, JJ; Kudelka, AP, 1993) |
| "Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk." | ( Costantino, JP; Cronin, WM; Fisher, B; Fisher, ER; Redmond, CK; Wickerham, DL, 1994) |
| "In addition, the relative risk of endometrial cancer observed in B-14 tamoxifen-treated patients is consistent with the twofold relative risk used in the initial risk-benefit computation for the NSABP breast cancer prevention trial." | ( Costantino, JP; Cronin, WM; Fisher, B; Fisher, ER; Redmond, CK; Wickerham, DL, 1994) |
| "Two unexpected endometrial carcinomas were observed at autopsy of rhesus monkeys treated for 10 years with 50 times the human doses of DMPA." | ( Lumbiganon, P, 1994) |
| "Surgical stage IC and II endometrial carcinomas involving the outer one third of myometrium and completely resected stage III and IV carcinomas were eligible for six cycles of cisplatin (Platinol), doxorubicin hydrochloride (Adriamycin), and cyclophosphamide (Cytoxan) (50, 50, 500 mg/m2), followed by external beam radiotherapy to pelvis, pelvis and periaortic chain, or whole abdomen, on the basis of documented disease." | ( Drescher, CW; Peters, WA; Smith, MR, 1994) |
| "The incidence of secondary endometrial cancer reported in this study following treatment of breast cancer patients with tamoxifen at doses of 40 mg/d in a large clinical trial is higher than that reported for previous large trials of tamoxifen at doses of 20 mg/d." | ( Fornander, T; Hellström, AC; Moberger, B, 1993) |
| "Patients with advanced or recurrent endometrial cancer of any cell type having measurable disease have been entered into this study to determine the effectiveness and toxicity of circadian-timed doxorubicin-cisplatin chemotherapy." | ( Barrett, RJ; Blessing, JA; Homesley, HD; Twiggs, L; Webster, KD, 1993) |
| "On dynamic studies of endometrial carcinoma, the tumor-myometrial contrast was marked at 120 seconds after administration of gadopentetate dimeglumine (contrast-to-noise ratio [C/N], 26." | ( Harada, M; Miyazaki, K; Okamura, H; Sawada, T; Takahashi, M; Yamashita, Y, 1993) |
| "2195 patients affected by endometrial carcinoma were treated at the Tbilisi and the St." | ( Charkviani, TL, 1993) |
| "Thirty-nine patients of endometrial cancer were treated with hydroxyprogesterone caproate, AG or combination of both, and their effects were compared." | ( Liu, XS; Zhang, X, 1995) |
| "One hundred and six patients with endometrial cancer were treated at Tsukuba University Hospital between 1983 and 1992." | ( Arisawa, Y; Ichikawa, Y; Kubo, T; Nishida, M; Nishide, K; Oki, A; Sato, T; Tsunoda, H, 1996) |
| "A significant increase in endometrial cancer incidence in tamoxifen-treated breast cancer patients has been reported in many recent studies." | ( Arbell, A; Danilenko, M; Karas, M; Kleinman, D; LeRoith, D; Levy, J; Roberts, CT; Sharoni, Y, 1996) |
| "We analyzed 76 patients with endometrial carcinoma treated in our department between January 1984 and July 1994." | ( Kato, J; Ogawa, K; Yasumizu, T, 1996) |
| "The incidence of endometrial cancer in women who receive combined estrogen-progestogen therapy is not elevated to nearly the same degree." | ( Hill, DA; Weiss, NS, 1996) |
| "The estimated annual risk of endometrial cancer in tamoxifen-treated patients is approximately 2 per 1,000 women." | ( Barakat, RR, 1995) |
| "Except for endometrial cancer, the incidence of second cancers was not increased with tamoxifen therapy." | ( Bowman, DM; Bryant, J; Costantino, J; DeCillis, A; Deschênes, L; Dignam, J; Dimitrov, NV; Evans, J; Farrar, W; Feldman, MI; Fisher, B; Fisher, ER; Lickley, HL; Margolese, RG; Paterson, AH; Redmond, C; Robidoux, A; Shibata, H; Terz, J; Wickerham, DL; Wolmark, N, 1996) |
| "Paclitaxel is active in patients with endometrial cancer pretreated with PAC." | ( Gabriele, A; Lissoni, A; Losa, G; Mangioni, C; Parma, G; Zanetta, G, 1996) |
| "The standard treatment for endometrial carcinoma is staging laparotomy with total abdominal hysterectomy and bilateral salpingo-oophorectomy." | ( Ghosh, K; Holschneider, CH; Kim, YB; Montz, FJ; Nieberg, RK, 1997) |
| "Only those patients with a diagnosis of endometrial carcinoma treated with progestin alone as primary therapy were included in the study." | ( Ghosh, K; Holschneider, CH; Kim, YB; Montz, FJ; Nieberg, RK, 1997) |
| "The two endometrial cancers occurred in women who were treated with tamoxifen for 6 years." | ( Bach, AM; Barakat, RR; Baum, HJ; Giess, CS; Hann, LE; Tao, Y, 1997) |
| "Since endometrial cancer consists of differentiated and undifferentiated cells as heterogeneity, a combination therapy for endometrial cancer with progestin and TNP470 might be effective." | ( Fujimoto, J; Hirose, R; Hori, M; Ichigo, S; Sakaguchi, H; Tamaya, T, 1997) |
| "AG also can be used to treat endometrial carcinoma." | ( Cao, B; Zhang, X, 1996) |
| "Since increased endometrial cancer incidence has not been observed in all studies of chronic tamoxifen therapy, there may be an element of detection bias." | ( Gelmann, EP; Stearns, V, 1998) |
| "Thus, p53 overexpression in endometrial carcinomas occurring in patients with breast cancer seems to be not specific for TAM-treated patients, and, if DNA adduct formation has any role in this type of endometrial carcinogenesis, it may not be related preferentially to p53 gene alteration." | ( Higashi, Y; Kasamatsu, T; Kishi, K; Kobayashi, Y; Kurosumi, M; Kuwashima, Y; Shiromizu, K; Suemasu, K; Tanuma, J, 1998) |
| "The mechanism of endometrial cancer associated with tamoxifen treatment is unclear, although there are two plausible hypotheses: (1), tamoxifen causes damage and mutation to DNA in uterine cells or (2), it promotes the development of endometrial tumors through its estrogen agonist activity." | ( Smith, LL; White, IN, 1998) |
| "Biopsy and hysterectomy specimens of 14 endometrial carcinomas (endometrioid-type) before and during progesterone therapy were studied to clarify changes in apoptosis and cell proliferation and their relation to morphologic alterations." | ( Okayasu, I; Saegusa, M, 1998) |
| "Twenty-nine evaluable patients with endometrial cancer were treated with amonafide 300 mg/m2 for 5 consecutive days every 3 weeks." | ( Asbury, R; Blessing, JA; McGuire, WP; Reid, GC, 1998) |
| "This paper reviews the reports of endometrial carcinoma in tamoxifen-treated patients." | ( Assikis, VJ; Jordan, VC, 1995) |
| "Thirty postmenopausal women with endometrial carcinoma were treated with 30 mg of tamoxifen daily for 7-10 days after curettage." | ( Babić, D; Dotlić, S; Ilić-Forko, J; Jukić, S; Marusić, M; Nola, M; Petrovecki, M; Skrablin, S; Suchanek, E; Uzarević, B, 1999) |
| "Four cases of clinical Stage I endometrial carcinoma initially treated with hormonal therapy are included in this study." | ( Anchezar Henry, JP; Gomez Rueda, N; Paniceres, G; Sardi, J; Vighi, S, 1998) |
| "We have treated a human endometrial cancer cell line which expresses GnRH receptor with GnRH analog, D-Trp6-LHRH, in order to study whether there are differences in cell cycle kinetic response." | ( Kim, BK; Kim, IK; Kim, JW; Lee, JM; Lee, YS; Namkoong, SE; Park, DC, 1999) |
| "Although an elevated occurrence of endometrial cancer is found in a small proportion of breast cancer patients treated with tamoxifen, there is conflicting evidence on whether or not low levels of DNA adducts are formed in humans." | ( Cheng, RH; Gant, TW, 1999) |
| "In patients with endometrial cancer the total Sia level before surgical treatment (709." | ( Barlas, P; Diamantopoulou, S; Karamanos, NK; Stagiannis, KD; Tsegenidis, T; Vasilopoulos, K, 1999) |
| "Endometrial polyps and endometrial neoplasms are a recognized complication of chronic tamoxifen treatment." | ( Esteller, M; Garcia, A; Martinez-Palones, JM; Reventos, J; Xercavins, J, 1999) |
| "In 29 women suffering from cervical or endometrial cancer two CT scans were carried out for treatment planning, one with an empty bladder and rectum, the second one with bladder and rectum filled." | ( Böhmer, D; Buchali, A; Budach, V; Dinges, S; Koswig, S; Lackner, G; Rosenthal, P; Salk, J; Schlenger, L, 1999) |
| "Moreover, in a human endometrial carcinoma cell line (COLO 684) OTR was demonstrated by immunofluorescence and RT-PCR and it was observed that OT treatment (10(-11)-10(-7) M) significantly inhibited cell proliferation." | ( Bussolati, G; Carcangiu, ML; Cassoni, P; Deaglio, S; Fulcheri, E; Stella, A, 2000) |
| "Patients with localized relapse of endometrial carcinoma in whom radical radiotherapy can be administered should be treated aggressively and may be cured in over half the cases treated." | ( Fyles, A; Irwin, C; Levin, W; Manchul, L; Milosevic, M; Pintilie, M; Wylie, J, 2000) |
| "However, non-endometrial cancer related deaths were more common in women treated with progestagens OR 1." | ( Jarvis, G; Kitchener, H; Lilford, R; Martin-Hirsch P, L, 2000) |
| "None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Mullerian mixed tumor." | ( Bourne, T; Dallenbach-Hellweg, G; Dören, M; Granberg, S; Hellberg, P; Kreuzwieser, E; Rudenstam, G; Rydh, W; Schmidt, D, 2000) |
| "Two women with endometrial carcinoma who wished to preserve their childbearing ability received conservative treatment by medroxyprogesterone acetate (MPA, 600 mg/day for 22 weeks and 29 weeks, respectively)." | ( Imai, M; Jobo, T; Kawaguchi, M; Kenmochi, M; Kuramoto, H, 2000) |
| "Patients with advanced or recurrent endometrial cancer not curable with either surgery or radiation therapy and with measurable disease, a GOG (Zubrod) performance status of < or = 2, no more than one prior hormonal therapy regimen, and no prior chemotherapy were eligible." | ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "No cases of endometrial carcinoma was found in our series of 34 patients with 1-2 years of tamoxifen treatment, and 1/78 in patients with 5-72 months of tamoxifen." | ( Andía, D; Lafuente, P; Matorras, R; Usandizaga, JM, 2000) |
| "We present a case of residual endometrial carcinoma after term pregnancy which had been treated conservatively before the pregnancy began." | ( Fujii, S; Kato, K; Konishi, I; Mitsushita, J; Toki, T, 2000) |
| "A 28-year-old woman with endometrial carcinoma received conservative treatment with high-dose medroxyprogesterone acetate (MPA) and then conceived." | ( Fujii, S; Kato, K; Konishi, I; Mitsushita, J; Toki, T, 2000) |
| "The risk to have an endometrial carcinoma during HRT is not increased, but endometrial cancers are more frequent with unopposed estrogen administration." | ( Birkhäuser, MH, 2000) |
| "The risk of endometrial cancer among users of continuous combined hormone replacement therapy (n = 9 case patients, n = 33 control subjects) relative to women who had never received hormone replacement therapy was 0." | ( Beresford, SA; Daling, JR; Hill, DA; Self, S; Stanford, JL; Voigt, LF; Weiss, NS, 2000) |
| "The numbers of endometrial cancers was 9 and 3 among tamoxifen-treated and non-tamoxifen-treated patients, respectively, and the IRR was 2." | ( Kimura, M; Koyama, H; Matsuyama, Y; Mitsuyama, S; Miura, S; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tominaga, T; Ueo, H, 2000) |
| "The young women with endometrial carcinoma localized in the endometrium who wish to preserve fertility may be treated as successfully with MPA as those with AH." | ( Fukunaga, M; Hataeg, M; Hiura, M; Iwasaka, T; Kaku, T; Kamura, T; Kodama, S; Kuwabara, Y; Kuzuya, K; Miyazaki, K; Nakano, H; Nishimura, T; Sakamoto, A; Sato, S; Tsuda, H; Yoshikawa, H, 2001) |
| "Only the risk of endometrial cancer in relation to tamoxifen treatment could be estimated." | ( De Vries, EG; Hollema, H; Mourits, MJ; Ten Hoor, KA; Van der Zee, AG; Willemse, PH, 2001) |
| "Fifteen cases of endometrial cancer were administered daily doses of 600 mg of MPA after surgery to prevent the recurrence of cancer." | ( Aisaka, K; Kaibara, M; Liang, SG; Okinaga, S; Ooka, F; Watanabe, T, 2001) |
| "Between 1992 and 1998, 43 high-risk endometrial cancer patients received adjuvant chemotherapy." | ( Connell, PP; McBride, R; Mundt, AJ; Rotmensch, J; Waggoner, SE; Yamada, SD, 2001) |
| "Treatment of endometrial carcinoma with high-dose medroxyprogesterone acetate could be an alternative to hysterectomy, although the successful rate is limited." | ( Imai, M; Jobo, T; Kawaguchi, M; Kuramoto, H; Sato, R, 2001) |
| "A retrospective review of 61 stage III endometrial carcinoma patients treated between 1988 and 1998 at Niigata University Hospital was performed." | ( Aoki, Y; Kase, H; Kurata, H; Sato, T; Tanaka, K; Watanabe, M, 2001) |
| "Treatment of Ishikawa and Hec-1A human endometrial cancer cells with 100 nM triptorelin resulted in a 3." | ( Emons, G; Gründker, C; Schlotawa, L; Viereck, V, 2001) |
| "In order to minimize the risks of endometrial cancer and the development of resistance to antiestrogen therapy, we have synthesized the orally active antiestrogen EM-652 which is the most potent of the known antiestrogens and exerts pure antiestrogenic activity in the mammary gland and endometrium." | ( Bélanger, A; Giguère, V; Labrie, C; Labrie, F; Simard, J; Tremblay, A; Tremblay, G, 2001) |
| "We report the delayed case of an endometrial carcinoma after an unusual twleve year long daily administration of Tamoxifen (cumulative dose = 131 g)." | ( Bailet, C; Hannoun-Lévi, JM; Largillier, R; Magné, N; Marcy, PY, 2001) |
| "Recently, we treated two patients with endometrial cancer with multiple lung metastases (FIGO stage IVb)." | ( Kanakura, Y; Kometani, K; Nakazawa, K; Niwa, K; Sekiya, T, 2002) |
| "The role of chemotherapy for metastatic endometrial carcinoma is palliation, although modest response can be achieved because of development of chemotherapy." | ( Katsumata, N; Kitagawa, R; Yamanaka, Y, 2002) |
| "Since endometrial cancer may become "silent" after initial bleeding, dilatation and curettage is indicated in all cases of postmenopausal vaginal bleeding, irregardless of estrogen therapy." | ( Paloucek, FP; Plotz, EJ, 1973) |
| "In patients with early endometrial cancer, adjuvant endocrine treatment did not significantly improve the outcome." | ( Brunnert, K; Kaufmann, M; Kreienberg, R; Loibl, S; Melchert, F; Mösch, R; Neises, M; Schermann, J; Seufert, R; Stiglmayer, R; Stosiek, U; von Minckwitz, G, 2002) |
| "To test this hypothesis, we treated endometrial cancer cells (Ishikawa cell line) with quercetin, and cell proliferation, expression of growth signal genes (EGF, VEGF, and TGF-alpha), cell cycle genes (p53, p21, p73, and cyclin D1), and apoptosis-related genes (bcl-2 and bax) were analyzed." | ( Dahiya, R; Fujimoto, S; Kaneuchi, M; Sakuragi, N; Sasaki, M; Tanaka, Y, 2003) |
| "In this high-risk population of endometrial cancer patients, it is necessary to have chemotherapy regimens with a low toxicity." | ( Bolis, G; de Oliveira, CF; Lhommé, C; Nooij, M; Scotto di Palumbo, V; Tumolo, S; van Wijk, FH; Vermorken, JB, 2003) |
| "Nine patients with recurrent endometrial cancer who had previously received chemotherapy or radiotherapy participated in the study, between May 1999 and August 2001." | ( Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K, 2003) |
| "To investigate the risk of endometrial cancer associated with various regimens of postmenopausal hormone therapy." | ( Newcomb, PA; Trentham-Dietz, A, 2003) |
| "Twenty-one post-operative patients with endometrial cancer received 30 FDG-PET examinations to evaluate recurrence or response to treatment." | ( Fujii, S; Fujita, T; Higashi, T; Higuchi, T; Ishimori, T; Kita, M; Konishi, J; Mamede, M; Mukai, T; Nakamoto, Y; Saga, T; Togashi, K; Yura, S, 2003) |
| "We herein report a case of endometrial cancer with metastasis to the lung in which multidisciplinary treatment including taxanes was effective." | ( Fushiki, H; Maeda, E; Yoshimoto, H, 2003) |
| "One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m2)." | ( Ito, K; Koizumi, T; Niikura, H; Okamura, K; Yaegashi, N, 2003) |
| "The best treatment for recurrent endometrial cancer is still uncertain, although weekly paclitaxel has shown some promise in the management of this disease." | ( Chang, SJ; Chen, HS; Chen, TC; Hsu, CY; Wang, TY; Yang, YC, 2003) |
| "Thirty untreated patients diagnosed as endometrial carcinoma through dilation and curettage of the uteri were divided into 3 groups at random." | ( Lan, SM; Li, CZ; Liu, Y; Wang, JY; Wen, ZQ, 2003) |
| "The analyzed endometrial carcinomas in Tamoxifen-treated breast cancer patients show signs, characteristic of Bochman type I: predominantly endometrioid, of low grade and FIGO stage, with good prognosis." | ( Gorchev, G; Ivanova, V; Karaivanov, M; Khristova, P; Marinov, E; Velkova, A, 2003) |
| "A panel of four endometrial carcinoma cell lines was treated with variable concentrations of gemcitabine, gemcitabine and cisplatin, or gemcitabine and carboplatin." | ( Brown, J; Martin, MC; Ramondetta, LM; Smith, JA; Wolf, JK, 2004) |
| "Young patients with endometrial cancer who desire to preserve their fertility often decline hysterectomy in favor of conservative progestin therapy." | ( Ben-Shachar, I; Cohn, DE; Vitellas, KM, 2004) |
| "A young patient with early-stage endometrial cancer initially declined surgery and was treated with megestrol." | ( Ben-Shachar, I; Cohn, DE; Vitellas, KM, 2004) |
| "Generally after treatment for endometrial cancer, current preference should be for low-dose oestrogen monotherapy rather than continuous combined therapy with progestogen addition in view of the increased risk of breast cancer and cardiovascular disease found with the latter regimen." | ( Mueck, AO; Seeger, H, 2003) |
| "We found that the rates of endometrial carcinoma and atypical hyperplasia were high in patients treated with Tamoxifen (7." | ( Gorchev, G; Ivanova, V; Karaivanov, M; Marinov, E; Raĭcheva, S, 2004) |
| "We treated a 32-year-old woman with endometrial cancer with multiple lung metastases (pT4N0M1)." | ( Kagami, T; Onoda, C; Tohya, T; Yoshimura, T, 2004) |
| "Increased risk of developing endometrial cancers has been observed in women treated with tamoxifen (TAM), a widely used drug for breast cancer therapy and chemoprevention." | ( Kim, SY; Laxmi, YR; Shibutani, S; Suzuki, N, 2004) |
| "In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer." | ( Driul, L; Marchesoni, D; Mozzanega, B; Nardelli, GB; Parenti, A, 2005) |
| "Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility." | ( Amezcua, C; Bahador, A; Burnett, AF, 2004) |
| "Ten patients with advanced endometrial cancer confined to the abdominal cavity and/or paraaortic lymph nodes with small residual disease were treated postoperatively with 3000 cGy whole abdominopelvic irradiation combined with 1500 cGy boost to the pelvis or pelvic and aortic fields." | ( Ashbury, R; Clarke-Pearson, DL; Jones, E; Reisinger, SA; Soper, JT, 2004) |
| "Primary treatment of endometrial cancer with progestogens is reserved for adjuvant or palliative treatment, although with unproven efficacy." | ( Butler-Manuel, S; Giannopoulos, T; Tailor, A, 2004) |
| "We present a case of early endometrial cancer where a combination of oral progestogens and levonorgestrel releasing intrauterine system (Mirena) was used as a primary treatment, as the standard surgical treatment was deemed to carry an unacceptable mortality risk." | ( Butler-Manuel, S; Giannopoulos, T; Tailor, A, 2004) |
| "CO2-VIBE was performed in 21 cases of endometrial carcinoma (Stage Ia-IIb) prior to treatment." | ( Abe, K; Akaeda, T; Isaka, K; Kakizaki, D; Takayama, M, 2005) |
| "Survival of 55 node-positive endometrial carcinoma patients prospectively treated with surgery and adjuvant chemotherapy between 1982 and 2002 at Hokkaido University Hospital was compared to various histopathologic variables." | ( Ebina, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H; Yamamoto, R, 2005) |
| "Among 303 consecutive endometrial cancer patients treated during the period of this study, 55 patients (18." | ( Ebina, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H; Yamamoto, R, 2005) |
| "Risk of endometrial cancer adjusted for treatment duration did not diminish in follow-up to at least 5 years after the last treatment ended." | ( Jones, ME; Swerdlow, AJ, 2005) |
| "There is an increasing risk of endometrial cancer associated with longer tamoxifen treatment, extending well beyond 5 years." | ( Jones, ME; Swerdlow, AJ, 2005) |
| "To treat experimental human endometrial cancers based on targeted chemotherapy with the cytotoxic luteinizing hormone-releasing hormone (LHRH) analogues AN-152 and AN-207." | ( Chism, DD; Engel, JB; Halmos, G; Keller, G; Nagy, A; Schally, AV, 2005) |
| "Moreover, we observed that endometrial carcinoma cell lines Ishikawa and KLE did not undergo apoptosis after TRAIL treatment." | ( Comella, JX; Dolcet, X; Llobet, D; Matias-Guiu, X; Pallares, J; Rue, M, 2005) |
| "When frozen sections of human endometrial carcinoma and lung carcinoma tissues were incubated on CCm-Tf films or those treated with proteinase inhibitors, the activity was detected in the carcinoma cell nests, where MMP-7 was immunolocalized." | ( Arakatsu, H; Hashimoto, G; Kataoka, F; Nemori, R; Okada, Y; Shiomi, T; Yamamoto, M, 2005) |
| "The rate of occurrence of endometrial cancer in 1026 tamoxifen-treated patients with breast cancer in our hospital between 1999 and 2001 was 1." | ( Abad, L; León, JP; Machado, F; Parrilla, JJ; Rodríguez, JR, 2005) |
| "Patients with metastatic endometrial carcinoma may respond to hormonal therapy with progestins." | ( Hoffman, MA; Khan, A, 2006) |
| "We report a patient with metastatic endometrial carcinoma to the lungs, who after progressing on progestin therapy, had a lengthy remission with anastrozole; upon further progression, fulvestrant (Faslodex) was instituted, with a resultant partial remission, which has been sustained for almost 3 years." | ( Hoffman, MA; Khan, A, 2006) |
| "PR- and GR-positive Ishikawa H endometrial cancer cells were treated with vehicle, dexamethasone (100 nM) or progesterone (100 nM) for 2 h, 6 h, 12 h and 24 h, and RNA was isolated." | ( Dai, D; Davies, S; Leslie, KK; Pickett, G, 2006) |
| "In cotreatment of endometrial cancer cells with ICI182780, values of OD 570 nm and numbers of apoptotic cells of Ishikawa cells decreased to basal levels, G0-G1 phase proportion increased, percentage of S phase increased in a time or time-dependent manner." | ( Guo, RX; Li, XP; Wang, JL; Wei, LH; Zhao, D, 2006) |
| "No cases of endometrial hyperplasia or endometrial cancer were reported with either treatment during the core or extension phase." | ( Arguinzoniz, M; Boschitsch, E; Concin, H; De Geyter, C; Ehrenborg, A; Heikkinen, J; Hobson, R; Ibarra de Palacios, P; Samsioe, G; Scheurer, C; Schmidt, G, 2006) |
| "The incidence of uterine endometrial cancer in the group with Hochu-ekki-to treatment was substantially lower than of the control group." | ( Mori, H; Niwa, K; Onogi, K; Tamaya, T; Tang, L; Yun, W, 2006) |
| "Four endometrial carcinoma cell lines (Ishikawa, ECC-1, RL-95-2 and Hec-1B) were treated with increasing concentrations of As2O3." | ( Bae-Jump, V; Boggess, JF; Gehrig, PA; Zhou, C, 2007) |
| "Increased risk for the development of endometrial cancer has been associated with unopposed oestrogen exposure, hyperoestrogenic factors, and a history of breast cancer treated long-term with tamoxifen (Tam)." | ( Jagodzinski, PP; Kubarek, Ł, 2007) |
| "By contrast, the risk of endometrial carcinoma increases with estrogen replacement therapy, while HRT reduces the risk of endometrial carcinoma." | ( Ito, K, 2007) |
| "ER-alpha measured in metastatic endometrial carcinoma tissue prior to hormonal therapy was statistically significantly related to clinical response to daily tamoxifen and intermittent medroxyprogesterone acetate." | ( Filiaci, VJ; Leslie, KK; Singh, M; Zaino, RJ, 2007) |
| "The data for patients with endometrial cancer stage III (n = 101) who had been treated at the McGill University Health Center between 1989 and 2003 were analyzed." | ( Denschlag, D; Gilbert, L; Kerim-Dikeni, A; Patel, S; Souhami, L; Tan, L, 2007) |
| "We report a case of endometrial cancer treated by fertility-preserving P therapy, who subsequently presented with an abnormal magnetic resonance imaging (MRI) of the myometrium despite normal endometrial biopsies." | ( Del Priore, G; Hartzfeld, KM; Hurst, SA, 2008) |
| "In patients with advanced/recurrent endometrial cancer treated with A, P and/or T, response was not associated with histology." | ( Filiaci, VL; Fleming, GF; Gallion, HH; McMeekin, DS; Rodgers, WH; Thigpen, JT, 2007) |
| "Hormone replacement therapy (HRT) after endometrial cancer (EMC) treatment is an uncertain subject with limited exploration among gynecologic cancer research." | ( Hanprasertpong, J; Kavanagh, JJ; Manusirivithaya, S; Tangjitgamol, S, 2008) |
| ": 356 Patients with advanced stage endometrial cancer were identified who received postoperative adjuvant therapies; 48% (n=171) radiotherapy alone, 29% (n=102) chemotherapy alone, 23% (n=83) chemotherapy and radiation." | ( Alvarez Secord, A; Bae-Jump, V; Berchuck, A; Bland, A; Calingaert, B; Chin, J; Clarke-Pearson, DL; Gehrig, PA; Havrilesky, LJ; Rutledge, TL, 2007) |
| "Specific endocrine treatment of endometrial carcinoma should be explored in future, although aromatase inhibitors are the most effective endocrine treatments of estrogen-responsive breast carcinoma." | ( Ito, K; Sasano, H; Utsunomiya, H; Yaegashi, N, 2007) |
| "In the 1970s, endometrial cancer incidence increased in developed countries, and exogenous estrogen therapy in postmenopausal women was the most important factor." | ( Araújo, NL; Athanazio, DA, 2007) |
| "HHUA, a rare endometrial cancer cell line expressing the estrogen receptor (ER), was adopted to investigate the expression of vascular endothelial growth factor (VEGF), erythropoietin (Epo), Bcl-2 and p53 under the administration of estradiol-17beta (E2)." | ( Honda, K; Ishiko, O; Nobeyama, H; Sumi, T; Yasui, T; Yoshida, H; Zhi, X, 2007) |
| "A review of cases with endometrial carcinoma that have been treated with conservative management and a subsequent assisted cycle is also presented here." | ( Ayhan, A; Bozdag, G; Demirol, A; Gurgan, T, 2007) |
| "Development of endometrial neoplasms and constitutive activation of the PI3K pathway in pten+/- mice is not affected by hormonal ablation or by progestin treatment." | ( Chapman, W; Fyles, A; Gowing, K; Khokha, R; Li, M; Manoukian, AS; Tsao, MS; Wood, G, 2008) |
| "This paper presents the first case of endometrial carcinoma following tamoxifen therapy for breast carcinoma in a 52 year old Nigerian female." | ( Abdul Kareem, FB; Abudu, EK; Adefuye, PO; Agboola, AO; Banjo, AA; Musa, O, 2007) |
| "In the treatment of endometrial carcinoma, young patients desire the preservation of the uterus, and therefore hormonal therapy has been administered." | ( Harashima, S; Hirashima, Y; Ito, I; Kawaguchi, R; Takahashi, N; Takekuma, M; Yamada, Y, 2008) |
| "Forty endometrial cancer patients staged Ib - IVa by the standard of Federation of International Gynecologic Organization (FIGO), who had not received any treatment were enrolled in this study." | ( Lei, X; Shan, JL; Tang, C; Zhao, KW, 2007) |
| "In patients with disseminated endometrial carcinoma, doxorubicin is used as a single agent or in combination therapy." | ( Balbi, G; Cardone, A; Manganaro, MA; Monteverde, A; Visconti, S, 2007) |
| "A panel of endometrial cancer cell lines with varying degrees of differentiation was treated with DCA and analyzed for apoptosis via flow cytometry." | ( De Vivo, I; Debidda, M; Huggins, GS; Munshi, NC; Wong, JY, 2008) |
| "Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer." | ( Alanbay, I; Dede, M; Gezginç, K; Güran, S; Ulubay, M; Yenen, M, 2008) |
| "A group of 18 patients with endometrial carcinoma following treatment with tamoxifen were selected." | ( Dahiya, S; Hardisson, D; Moreno-Bueno, G; Oliva, E; Palacios, J; Prat, J; Sánchez-Estevez, C; Turbiner, J, 2008) |
| "Sixty-one patients with endometrial carcinoma who underwent surgical treatment consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal cytology were retrospectively analyzed." | ( Bilir Dilek, G; Metindir, J, 2009) |
| "Standard chemotherapy for endometrial cancer, including therapy with adriamycin and cisplatin (AP therapy), has not been established." | ( Kushimoto, T; Misawa, A; Nagao, M; Yasuda, M, 2008) |
| "In Stage IIIc endometrial cancer, combined treatment with RT and CT reduces pelvic recurrence and improves progression-free survival and overall survival compared with CT alone." | ( Ito, E; Matsuura, M; Morishita, M; Saito, T; Suzuki, T; Tanaka, R, 2009) |
| "Because endometrial cancer (EMC) patients frequently present at an early stage of disease, most have favorable outcomes, thus their quality of life after treatment is as important a consideration as a cure of cancer." | ( Hanprasertpong, J; Manusirivithaya, S; Tangjitgamol, S, 2009) |
| "Our aim was to determine the risk of endometrial cancer associated with long-term use of combined hormone therapy (HT) and low-potency estrogens." | ( Epstein, E; Lindqvist, PG; Olsson, H, 2009) |
| "At the end of the treatment the endometrial cancer remitted to simple endometrial hyperplasia." | ( Bogliatto, F; Leidi, L; Morero, S; Mosso, L; Sodano, M; Torchio, B, 2009) |
| "Treatment of endometrial cancer cells with 5-azacytidine could reactivate MT-1E expression." | ( Chan, DW; Chan, KK; Cheung, AN; Chiu, PM; Liao, XY; Liu, VW; Ngan, HY; Tam, KF; Tse, KY, 2009) |
| "The optimal palliative chemotherapy in endometrial cancer is unknown." | ( Idris, T; Lang, U; Petru, E; Winter, R, 2009) |
| "Human endometrial cancer cells (HEC-1A) were treated with 0." | ( Fedier, A; Kurmanaviciene, A; Minder, EI; Roos, M; Roth, M; Schneider-Yin, X; Walt, H, 2009) |
| "Patients with endometrial cancer with transperitoneal spread, as determined by laparoscopy (+/-pleural effusion), were treated with NACT." | ( Amant, F; Berteloot, P; Capoen, A; Leunen, K; Moerman, P; Neven, P; Van Calster, B; Vandenput, I; Vergote, I, 2009) |
| "However, its usefulness for treating endometrial cancer has not yet been fully explored." | ( Chang, TC; Chen, CH; Chen, RJ; Chien, CH; Chow, SN; Lee, WJ, 2009) |
| "The treatment of endometrial cancer in young women who want to preserve their fertility is challenging." | ( Amant, F; Moerman, P; Van Eygen, K; Vandenput, I; Vergote, I, 2009) |
| "A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year." | ( Aoki, D; Kitagawa, R; Sagae, S; Sakuragi, N; Takeuchi, S; Watanabe, Y; Yaegashi, N, 2009) |
| "Hec1A endometrial cancer cells (Hec1A/V) and Hec1A cells with siRNA knockdown of ER-alpha36 (Hec1A/RNAi) were treated with testosterone, ERK and Akt phosphorylation was assessed by Western blot analysis." | ( Liang, XW; Lin, SL; Qiao, J; Schatten, H; Sun, QY; Wang, ZB; Wang, ZY; Yan, LY, 2009) |
| "Representative endometrial carcinoma cells with wild type or mutant endogenous PTEN were treated with the glucose analog 2-deoxyglucose (2-DG) and rapamycin, an mTOR inhibitor or cisplatin." | ( Daudi, S; Griffith, K; Kshirsagar, M; Liu, JR; Rhode, J; Tan, L; Wahl, H, 2010) |
| "To estimate the risk of endometrial cancer in all Finnish postmenopausal women using various forms of estradiol-progestin therapy." | ( Jaakkola, S; Lyytinen, H; Pukkala, E; Ylikorkala, O, 2009) |
| "This is the first time that endometrial cancer has been reported as a complication of tamoxifen therapy in the absence of a uterus." | ( Grimes, C; Lalude, O, 2010) |
| "Four of six patients with endometrial cancer had initial response to progesterone therapy and obtained complete response; three among them had successful pregnancies with three live births." | ( Chen, Y; Lv, W; Mao, Y; Wan, X; Xie, X, 2010) |
| "Forty patients with endometrial cancer and 10 with cervical cancer underwent pre-operative LSG with 1 or 4 mCi of (99m)Tc sulfur colloid administered as injections into the cervix." | ( Abu Rustum, NR; Barakat, RR; Gemignani, ML; Larson, SM; Lyall, A; Pandit-Taskar, N, 2010) |
| "The preclinical data for endometrial cancer treatment using MEDI-547 show substantial antitumor activity." | ( Coleman, RL; Gooya, J; Han, HD; Jackson, D; Jennings, NB; Kim, HS; Lee, JW; Lee, SJ; Mangala, LS; Mao, S; Nam, EJ; Nick, AM; Roh, JW; Shahzad, MM; Sood, AK; Stone, RL, 2010) |
| "Premenopausal women with early endometrial cancer may wish to maintain their fertility, and for some patients non-surgical treatment options may be attractive." | ( Cade, TJ; Neesham, D; Quinn, MA; Rome, RM, 2010) |
| "From 1988 to 2008, 111 endometrial cancer patients underwent total abdominal hysterectomy and adjuvant whole pelvic radiation therapy (RT)." | ( Kawana, K; Nakagawa, K; Nakagawa, S; Oda, K; Okuma, K; Yamashita, H, 2010) |
| "Thirteen fresh endometrial cancer tumor explants (nine Type I, four Type II) were placed in short-term culture and treated with rapamycin." | ( Bae-Jump, VL; Barroilhet, L; Boggess, JF; Gehrig, PA; Whang, YE; Zhou, C, 2010) |
| "When we treated endometrial cancer cells with specific anti-miRs, including anti-miR-141, -200a, -200b, -200c, or -429, we found that anti-miR-200a, -200b, -200c, and -429 significantly inhibited the growth of HEC-1A cells and anti-miR-141, -200c, and -429 significantly inhibited the growth of Ishikawa cells." | ( Bae, DS; Choi, C; Choi, JJ; Kim, BG; Kim, CJ; Kim, TJ; Lee, JW; Lee, NW; Lee, YY; Park, YA, 2011) |
| "Ishikawa endometrial cancer control cells transfected with an empty expression vector, Ishikawa cells with shRNA knockdown of ER-α36 (Ishikawa/RNAiER36) and Ishikawa cells with shRNA knockdown of ER-α66 (Ishikawa/RNAiER66) were treated with E2 and E2-conjugated to bovine serum albumin (E2-BSA, membrane impermeable) in the absence and presence of different kinase inhibitors HBDDE, bisindolylmaleimide, rottlerin, H89 and U0126." | ( Fu, XQ; Hou, Y; Li, S; Sheng, J; Sun, QY; Tong, JS; Wang, ZB; Wang, ZY; Yang, CR; Zhang, QH, 2010) |
| "Samples from the women with endometrial cancer was associated with higher Ki-67 expression compared with the polyp samples from TAM-treated women (P = 0." | ( Cândido, EB; da Silva Filho, AL; Freitas, GF; Lages, EL; Lamaita, RM; Miranda, SP; Traiman, P; Vidigal, PV, 2010) |
| "The study presents a case of endometrial cancer in a breast cancer patient treated with tamoxifen." | ( Beculić, H; Dervisević, S; Fajkić, A; Mekić-Abazović, A; Musić, M, 2011) |
| "The treatment of advanced endometrial cancer remains a challenge and the range of valuable treatments remains limited." | ( Eichbaum, M; Mayer, C; Reinhardt, J; Schott, S; Sohn, C, 2011) |
| "Effective treatments for advanced endometrial cancer are lacking." | ( Dewdney, SB; Gao, F; Goodfellow, PJ; Huettner, P; Mutch, DG; Rimel, BJ; Schmidt, A; Thaker, PH; Thompson, DM, 2011) |
| "In this paper, the different types of endometrial cancer, staging, prognosis, diagnosis, prevention, treatment and their relationship to estrogen and other female hormones are reviewed." | ( Ulrich, LS, 2011) |
| "COX-2 is highly expressed in endometrial cancers, suggesting that a selective COX-2 inhibitor could be valuable for treating endometrial cancers that overexpress COX-2." | ( Hasegawa, K; Ishii, R; Kato, R; Oe, S; Torii, Y; Udagawa, Y, 2011) |
| "Surgical specimens from COX-2 positive endometrial cancer patients treated with etodolac had significantly reduced expression levels of COX-2, Ki-67, p53, p21, p27, and cyclin D1 as determined by immunohistochemistry, while AI was not affected." | ( Hasegawa, K; Ishii, R; Kato, R; Oe, S; Torii, Y; Udagawa, Y, 2011) |
| "We undertook a study on 194 endometrial cancer patients who underwent primary treatment in the Gynecologic Clinic, Democritus University of Thrace." | ( Anastasiadis, P; Dimitraki, M; Galazios, G; Koutlaki, N; Liberis, A; Liberis, V; Tsikouras, P, 2011) |
| "A rare case of endometrial carcinoma that presented wth symptoms of bone metastasis in the right ischium and treated successfully by zoledronic acid is described." | ( Furukawa, N; Haruta, S; Kawaguchi, R; Kobayashi, H; Nagai, A; Ooi, H; Shigemitsu, A; Tanase, Y; Yamada, Y; Yoshida, S, 2011) |
| "We cultured 6 endometrial cancer cell lines exposed to paclitaxel, studied the cell cytotoxicity, cell cycle distribution, CHFR expression, and methylation status before and after a demethylation agent (5-aza) treatment." | ( Li, T; Li, X; Shen, H; Wang, X; Xiao, L; Xu, C; Yang, Y; Zhang, X, 2011) |
| "The increase of endometrial cancer survivors' incidence let the question if the management of postmenopausal hormone therapy will increase the risk of carcinogenesis." | ( Arteaga-Gómez, AC; Castellanos-Barroso, G; Colin-Valenzuela, A; García-Vargas, J; Márquez-Acosta, G; Reyes-Muñoz, E, 2011) |
| "Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive." | ( Di Legge, A; Lorusso, D; Moruzzi, MC; Pesce, A; Scambia, G; Trivellizzi, IN, 2011) |
| "A total of 35 patients with endometrial carcinoma diagnosed by endometrial sampling were examined with transvaginal sonography followed by contrast-enhanced sonography before treatment." | ( Dai, Q; Gao, P; Jiang, YX; Liu, ZZ; Yang, M; Zhao, DC; Zhu, QL, 2011) |
| "The treatment of endometrial cancer in young women who desire future fertility poses several challenges." | ( Broaddus, RR; Brown, AJ; Schmeler, K; Westin, SN, 2012) |
| "Advanced endometrial cancer often shows resistance to clinical chemotherapy although potencies of anticancer drugs in vitro are promising." | ( Chitcholtan, K; Evans, JJ; Sykes, PH, 2012) |
| "We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin." | ( Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA, 2011) |
| "While early-stage endometrial cancer is often successfully treated with surgical intervention, treatment of advanced endometrial carcinoma can be difficult and prognosis poor, particularly in the context of metastatic or recurrent disease." | ( Dizon, DS; Hill, EK, 2012) |
| "Patients with primary M1 endometrial carcinoma who received (18)F-FDG PET/CT before treatment were retrospectively analyzed." | ( Chao, A; Chou, HH; Lai, CH; Liu, FY; Yen, TC, 2012) |
| "And the MTT assay was performed in endometrial cancer cells following anti-miR-155 and AGTR1 blocker (losartan) treatment, alone and in combination." | ( Bae, DS; Choi, CH; Choi, JJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Park, YA; Song, SY; Song, T, 2012) |
| "The main methods of treatment of endometrial carcinoma are hysterectomy and bilateral oophorectomy with lymphadenectomy." | ( Bae, J; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Nam, JH; Suh, DS; Won, M, 2012) |
| "Chemotherapy options for advanced endometrial cancer are limited and newer therapeutic agents are urgently needed." | ( Brard, L; Choi, JS; Horan, TC; Kim, K; Kristjansdottir, K; Moore, RG; Singh, RK, 2012) |
| "Patients with endometrial cancer after breast cancer who received tamoxifen treatment for five years for breast cancer have greater endometrial cancer mortality risk than those who did not receive tamoxifen." | ( Bernstein, L; Hollema, H; Hoogendoorn, WE; Jones, ME; Mourits, MJ; Press, MF; Swerdlow, AJ; van Boven, H; van Leeuwen, FE, 2012) |
| "Chemotherapy is used when endometrial carcinoma is associated with widespread metastasis or when the tumor recurs after radiation therapy." | ( Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A, 2012) |
| "Twenty-six consecutive high-risk endometrial cancer patients requiring adjuvant radiation to the vaginal cuff and regional lymph nodes were treated with vaginal cuff fiducial-based IGRT." | ( Monroe, AT; Peddada, AV; Pikaart, D, 2013) |
| "Cell viability of ovarian and endometrial cancer cells treated without or with glycolysis inhibitor 2-Deoxy-D-Glucose (2DG) alone or in combination with GnRH-II antagonist [Ac-D2Nal(1), D-4Cpa(2), D-3Pal(3,6)(8),Leu, D-Ala(10)]GnRH-II or with cytotoxic GnRH-I agonist AEZS-108 (AN-152) was measured using alamar blue assay." | ( Emons, G; Gründker, C; Reutter, M, 2013) |
| "However, endometrial cancer patients with K-RAS mutations do not seem to derive benefit from everolimus treatment." | ( Alexandre, J; Bonichon-Lamichhane, N; Bonnin, N; Cretin, J; Freyer, G; Gane, N; Lavau-Denes, S; Lebrun, D; Mari, V; Petit, T; Pissaloux, D; Priou, F; Ray-Coquard, I; Trédan, O; Treilleux, I; Wang, Q, 2013) |
| "Human endometrial cancer cell lines Ishikawa and HEC-1A were treated with 5-aza-CdR." | ( Hu, Q; Liao, QP; Yu, L, 2012) |
| "Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy." | ( Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nogami, Y; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Umene, K; Yamagami, W; Yanokura, M, 2013) |
| "The treatment records of patients with endometrial cancer who received PLD at The University of Texas, MD Anderson Cancer Center, from 1996 to 2006 were reviewed." | ( Coleman, RL; Julius, JM; Nogueras-Gonzalez, GM; Smith, JA; Tanyi, JL; Watkins, JL; Wolf, JK, 2013) |
| "A total of 268 women with endometrial cancer or atypical endometrial hyperplasia underwent FDG PET/CT imaging before surgical treatment." | ( Andersen, ES; Antonsen, SL; Asmussen, J; Berthelsen, AK; Christensen, IJ; Fagö-Olsen, CL; Fisker, R; Høgdall, C; Høgdall, E; Jochumsen, K; Loft, A; Nielsen, AL; Tabor, A, 2013) |
| "A 58-year-old woman with endometrial carcinoma, in whom pyomyositis developed during adjuvant chemotherapy, was presented in this report." | ( Aihara, S; Hashiguchi, M; Iwasaka, T; Nakao, Y; Nishiyama, S; Noguchi, M; Yasunaga, M; Yokoyama, M, 2013) |
| "The ten-year cumulative risk of endometrial cancer in women who were treated with tamoxifen was 2." | ( Foulkes, WD; Ghadirian, P; Gronwald, J; Iqbal, J; Karlan, B; Kim-Sing, C; Lubinski, J; Lynch, HT; Moller, P; Narod, SA; Neuhausen, SL; Ping, S; Rosen, B; Segev, Y; Senter, L; Singer, CF; Tung, N, 2013) |
| "Among patients with advanced endometrial carcinoma who had received adjuvant paclitaxel/carboplatin, treatment with doxorubicin at time of disease recurrence failed to achieve any objective responses and was associated with a very short (2 months) time to progression." | ( Aghajanian, CA; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2013) |
| "Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes." | ( Bougnoux, P; Fabbro, M; Favier, L; Floquet, A; Joly, F; Paraiso, D; Plantade, A; Pujade-Lauraine, E; Ray-Coquard, I; Roemer-Becuwe, C; Weber, B, 2013) |
| "To estimate the survival of endometrial cancer patients based on age, education, family history, tobacco habit, number of pregnancies, clinical extent of disease and treatment received." | ( Balasubramaniam, G; Mahantshetty, U; Rasika, B; Sushama, S, 2013) |
| "Using an in vivo endometrial cancer mouse model driven by clinically relevant genetic changes but dichotomous responses to hormonal therapy, we show that signaling through stromal PR is necessary and sufficient for progesterone antitumor effects." | ( Iruela-Arispe, ML; Janzen, DM; Lee, DS; Memarzadeh, S; Paik, DY; Rosales, MA; Smith, DA; Witte, ON, 2013) |
| "557 patients treated for endometrial carcinoma were prospectively included in a study focusing on the relationship between preoperative hemoglobin, leukocyte and platelet counts, and a panel of clinicopathological characteristics and outcome." | ( Engerud, H; Njølstad, TS; Salvesen, HB; Trovik, J; Werner, HM, 2013) |
| "Patients with high-risk early stage endometrial carcinoma treated with adjuvant chemoradiotherapy have a low rate of recurrence compared to those not receiving such therapy." | ( Aquino-Parsons, C; Hoskins, P; Jutzi, L; Kwon, JS; Lim, P; Tinker, A, 2013) |
| "Moreover, in HEC108 cells, another endometrial cancer cell line, UA treatment decreased cyclin D1, pERK1/2, and Cullin1 levels in a dose- and time-dependent manner and UA markedly inhibited FBXW8." | ( Achiwa, Y; Hasegawa, K; Udagawa, Y, 2013) |
| "Inclusion criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine abdomen-confined disease, treated with WAI as part of multimodal therapy." | ( Delaney, TF; Kahn, RS; Niemierko, A; Rochet, N; Russell, AH, 2013) |
| "Advanced or recurrent endometrial cancer (EC) no longer amenable to surgery or radiotherapy is a life-threatening disease with limited therapeutic options left." | ( Beckmann, MW; Dall, P; Emons, G; Gorchev, G; Gründker, C; Hanker, L; Harter, P; Hilpert, F; Sehouli, J; Sindermann, H; Stähle, A; Wimberger, P, 2014) |
| "We observed that L1CAM positive endometrial carcinoma (EC) cell lines HEC1B and SPAC1L lost L1CAM protein and mRNA by treatment with demethylating agents or knock-down of the DNA-methyltransferase-1 (DNMT1)." | ( Altevogt, P; Bretz, NP; Breunig, C; Doberstein, K; Fiegl, H; Kiefel, H; Müller-Holzner, E; Rupp, AK; Schirmer, U; Schuster, E; Sültmann, H; Wuttig, D; Zeillinger, R; Zeimet, AG, 2014) |
| "We treated three endometrial cancer cell lines with various concentrations of telmisartan, and we investigated the effects of the telmisartan on the cell proliferation, apoptosis, and their related measurements in vitro." | ( Furukawa, Y; Ishii, T; Koyama, N; Narahara, H; Nishida, Y; Yoshida, T, 2014) |
| "The "gold standard" treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements." | ( Chao, HT; Chao, KC; Lee, FK; Lee, WL; Ng, HT; Wang, PH; Yen, MS; Yuan, CC, 2014) |
| "These new findings about endometrial cancer suggest a potential for targeted therapy with lapatinib, a dual inhibitor of epidermal growth factor receptor and HER2 tyrosine kinases." | ( Chang, TC; Chao, A; Chao, AS; Chou, HH; Hsueh, S; Huang, HJ; Lai, CH; Lee, YS; Lin, CY; Wang, TH; Wu, TI, 2014) |
| "Women with stage III-IV endometrial cancer treated with concurrent chemotherapy and radiation between 2006 and 2013 were included." | ( Al-Hammadi, N; Binder, PS; Fuh, K; Grigsby, P; Hagemann, A; Mutch, D; Pourabolghasem, S; Powell, M; Schwarz, J; Thaker, P; Wilkinson-Ryan, I, 2014) |
| "The standard treatment of advanced endometrial cancer consists of cytoreductive surgery followed by radiation therapy, or chemotherapy, or both." | ( Al Moundhri, M; Bryant, A; Galaal, K; Lawrie, TA; Lopes, AD, 2014) |
| "Between 1999 and 2007, 43 patients with endometrial cancer were treated with carboplatin and epirubicin." | ( Anwar, S; Barthakur, U; El-Modir, A; Fernando, I; Tirmazy, SH, 2014) |
| "The underlying causes of endometrial cancer (EMC) are poorly understood, and treatment options for patients with advanced stages of the disease are limited." | ( Cappelletti, M; Daikoku, T; Dey, SK; Ellenson, LH; Hossain, MM; Terakawa, J; Yang, P; Yoshie, M, 2014) |
| "Ishikawa cells, human endometrial cancer cells, were treated with estrogen." | ( Ma, X; Sun, Y; Wang, C; Yang, H, 2014) |
| "We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3)." | ( Alran, S; Brugier, C; de la Rochefordière, A; Féron, JG; Fourchotte, V; Malhaire, C; Ngô, C; Plancher, C; Rouzier, R; Sastre, X; Scholl, S, 2014) |
| "Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen." | ( Alran, S; Brugier, C; de la Rochefordière, A; Féron, JG; Fourchotte, V; Malhaire, C; Ngô, C; Plancher, C; Rouzier, R; Sastre, X; Scholl, S, 2014) |
| "Some endometrial carcinomas respond to hormonal therapy, but the mechanism of action remains incompletely known." | ( Brady, WE; Duska, LR; Fischer, EG; Horowitz, NS; Ivanovic, M; Leslie, K; Mannel, RS; Todd, W; Walker, JL; Zaino, RJ, 2014) |
| "Women treated for endometrial cancer (n = 1243) were followed-up 3-5 years after diagnosis; a subset of 643 completed a follow-up survey that asked about lymphedema and lymphedema-related support needs." | ( Beesley, VL; Brand, A; Hayes, SC; Janda, M; Leung, Y; Marquart, L; McQuire, L; O'Rourke, P; Obermair, A; Oehler, MK; Quinn, MA; Rowlands, IJ; Spurdle, AB; Webb, PM, 2015) |
| "The hazard ratio for development of endometrial cancer among breast cancer survivors aged 20-79 years who had taken dang-qui after tamoxifen treatment was decreased compared to survivors who had never used dang-qui (HR: 0." | ( Lai, JN; Tsai, YT; Wu, CT, 2014) |
| "Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis." | ( Backes, F; Birrer, M; Campana, F; Egile, C; Ghamande, S; Martin, LP; Matulonis, U; McMeekin, S; Vergote, I; Xu, Y, 2015) |
| "Patients with endometrial cancer were enrolled after treatment." | ( Hisamatsu, T; Ito, K; Kamiura, S; Kimura, T; Mabuchi, S; Morishige, K; Nakamura, K; Nishio, Y; Sawada, K; Sugiyama, M, 2015) |
| "Human endometrial cancer cell lines Ishikawa and HEC-1A underwent treatment with metformin at various concentrations (0." | ( Chen, F; Liu, T; Liu, Y; Xu, H; Yin, Z; Zhang, B; Zhang, J; Zhou, X, 2014) |
| "Although there were somewhat fewer endometrial cancers in the aromatase inhibitor group versus the no endocrine therapy group, further studies are needed for the definitive assessment of this potential association." | ( Chlebowski, RT; Chung, J; Haque, R; Schottinger, JE; Shi, J, 2015) |
| "Analyses were stratified by endometrial cancer type, and potential effect modification by parity, obesity, and hormone replacement therapy (HRT) use was investigated." | ( Baandrup, L; Brøns, N; Dehlendorff, C; Kjaer, SK, 2015) |
| "Surgically-treated patients with endometrial carcinoma had their tumors stained for nuclear expression of cyclin D1 and E." | ( Geisler, JP; Manahan, KJ; Miller, GA; Zapiecki, K, 2015) |
| "For platinum-resistant recurrent endometrial cancer patients, Tax-C may be preferred over AP as second-line chemotherapy." | ( Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H, 2015) |
| "Fifty-four patients with endometrioid endometrial cancer underwent routine surgical therapy and sentinel lymph node biopsy (SLNB)." | ( Kobierski, J; Lass, P; Liro, M; Sawicki, S; Wojtylak, S; Wydra, D, 2015) |
| "Randomly'assign the human endometrial carcinoma cell line HEC-1-B into groups and use demethylating drug 5-Aza-CdR of different concentration to treat them." | ( Chen, C; Huang, LP; Liu, H; Wang, XP, 2015) |
| "Aberrant methylation of RASSF1A in endometrial cancer as a therapeutic target, demethylating agent 5-Aza-CdR could be an effective way of gene therapy." | ( Chen, C; Huang, LP; Liu, H; Wang, XP, 2015) |
| "Fertility-sparing treatment for endometrial cancer (EC) with progestin is associated with a high chance of disease regression, and the high relapse rate continues to be a problem." | ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| "Eligible patients had a diagnosis of endometrial cancer based on histology and treated with an adjuvant chemotherapy regimen comprising taxane-platinum after surgery, and the HER2 and TOP2A status of the endometrial cancer regions was determined." | ( Furukawa, N; Ito, F; Nakai, T, 2016) |
| "The adjuvant treatment of high-risk endometrial cancer (HREC) remains controversial." | ( Huang, X; Ren, Y; Shan, B; Shi, D; Wang, H; Wu, X, 2016) |
| "As the number of younger women with endometrial carcinoma has increased, fertility-sparing treatments have received more attention." | ( Honda, R; Katabuchi, H; Ohba, T; Saito, F; Suzuki, A; Tashiro, H; Yamaguchi, M, 2016) |
| "In a clinical project, we identified 12 endometrial cancer patients who were treated with progestin drugs at our institution." | ( Behbakht, K; Guy, MS; Post, MD; Qamar, L; Sartorius, CA; Sheeder, J; Spillman, MA, 2016) |
| "Treatment of the endometrial cancer with cytoreductive surgery followed by adjuvant chemotherapy was performed first." | ( Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H, 2015) |
| "About one third of patients with endometrial cancer (EC) relapse and face a limited prognosis, if surgery or radiotherapy are not feasible." | ( Battista, MJ; Schmidt, M, 2016) |
| "Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy." | ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016) |
| "Ishikawa human endometrial cancer cells were treated with ERα ligands such as 17β-estradiol (E2), CC, and the pure antiestrogen, ICI 182,780 (ICI)." | ( Amita, M; Igarashi, H; Nagase, S; Takahashi, T, 2016) |
| "A 75-year-old woman with endometrial cancer received doxorubicin as part of her treatment." | ( Côté, B; Vadeboncoeur, S, 2016) |
| "We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy." | ( Aoki, D; Banno, K; Chiyoda, T; Hirasawa, A; Kataoka, F; Makabe, T; Ninomiya, T; Nomura, H; Sakai, K; Susumu, N; Takigawa, A; Wada, M; Yamagami, W, 2016) |
| "Metformin may reduce the risk of endometrial cancer whereas other drugs for the treatment of type 2 diabetes mellitus appear to increase it, although the evidence is still limited." | ( Asciutto, R; Bosetti, C; Corrao, G; Franchi, M; La Vecchia, C; Merlino, L; Nicotra, F, 2017) |
| "The increasing incidence of endometrial cancer (EC), in younger age at diagnosis, calls for new tissue-sparing treatment options." | ( Almomen, A; Dodson, MK; Janát-Amsbury, MM; Jarboe, EA; Owen, SC; Peterson, CM, 2016) |
| "A human endometrial carcinoma cell line, Ishikawa cells, was cultured in vitro and treated with mifepristone at different concentrations." | ( Li, MJ; Lu, ZZ; Yan, L; Zhang, H; Zhang, XH; Zhao, XX, 2016) |
| "Women with high-risk endometrial cancer were randomly allocated (1:1) to radiotherapy alone (48·6 Gy) in 1·8 Gy fractions five times a week or chemoradiotherapy (two cycles concurrent cisplatin 50 mg/m(2) and four adjuvant cycles of carboplatin area under the curve [AUC] 5 and paclitaxel 175 mg/m(2)) using a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type." | ( Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW, 2016) |
| "Sixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis." | ( Cai, D; Feng, M; Qi, Y; Sun, H; Wu, X; Zhao, X, 2016) |
| "The traditional treatment of endometrial cancer is based on a surgical approach." | ( Bogliolo, S; Cassani, C; Dominoni, M; Ferrero, S; Gardella, B; Iacobone, AD; Orlandini, A; Spinillo, A; Venturini, PL; Viazzo, F, 2017) |
| "Hormone therapy and endometrial cancer risk, trabectedin as an option for leiomyosarcoma, endometrial cancer and Lynch syndrome, and the radiation therapy guidelines were also discussed." | ( Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH, 2016) |
| "The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy." | ( de Waal, YR; Leenders, W; Ottevanger, PB; Tops, B; van der Steen, MJ; Westermann, A, 2016) |
| "HEC-1-A and Ishikawa endometrial carcinoma cell lines and three tumor cell lines were treated by different concentrations of carfilzomib." | ( Luo, W; Wang, K; Wang, R; Zhen, S; Zhou, Y, 2016) |
| "This case highlights the possibility of endometrial carcinoma despite treatment with an LNG 52 mg-IUS and reinforces the importance of investigating women who present with unusual persistent or heavy vaginal bleeding." | ( Briggs, P; Thomas, M, 2017) |
| "We retrospectively identified endometrial cancer patients treated with paclitaxel (175 mg/m per 3 hours), carboplatin (area under the curve, 5) and bevacizumab (15 mg/kg) and maintenance bevacizumab treated in a post-protocol treatment cohort and evaluated them with our previously published phase 2 trial of this regimen." | ( Ali, S; Moslemi-Kebria, M; Rose, PG; Simpkins, F, 2017) |
| "Advanced and recurrent endometrial carcinoma (EC) exhibits a poor response to chemotherapy and low survival rates." | ( Chong, QY; Ding, K; Kong, X; Li, R; Li, X; Lobie, PE; Ma, L; Pandey, V; Qian, P; Wu, Z; Xiong, Z; Yang, Y; Yuan, Y; Zhu, T, 2017) |
| "Ishikawa endometrial cancer cells were treated with BSO and AAPH to mimick oxidative stress conditions." | ( Etzl, R; Faigle, G; Heublein, S; Jeschke, U; Kuhn, C; Makrigiannakis, A; Navrozoglou, I; Rotzoll, D; Stefos, T; Vrekoussis, T, 2017) |
| "Four human endometrial cancer cell lines, ECC, HEC1A, HEC108 and TEN, were treated with PD-0332991 and their function was evaluated." | ( Ashihara, K; Fujiwara, S; Ohmichi, M; Sasaki, H; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S, 2017) |
| "122 patients with endometrial cancer were included in the study, of these, 61 patients received the dose dense protocol and 61 were treated with the standard 3-weekly protocol." | ( Abitbol, J; Amajoud, Z; Eisenberg, N; Fatnassi, A; Gotlieb, WH; Kessous, R; Kogan, L; Laskov, I; Lau, S; Octeau, D; Salvador, S; Yasmeen, A, 2017) |
| "Patients with endometrial cancer and a preoperative F-fluorodeoxyglucose positron emission tomography/computed tomography before curatively intended treatment were included." | ( Hess, S; Jochumsen, KM; Lund, AA; Vilstrup, MH, 2017) |
| "Tumor xenografts of human endometrial cancer were established and subjected to microarray analysis after Pro-EGCG treatment." | ( Chan, TH; Kwong, J; Man, GCW; Wang, CC; Wang, J, 2018) |
| "These observations were reinforced in endometrial cancer cells by PD98059 treatment." | ( Ding, Y; Jiang, J; Lu, B; Ma, Y; Xu, T; Zhang, Y, 2017) |
| "Sixty-five patients diagnosed as endometrial carcinoma were grouped into (n = 33) and non-treatment mixed (n = 32) for analysis." | ( Cai, D; Feng, M; Sun, H; Wan, Q; Zhao, J; Zhao, X; Zhao, Y, 2018) |
| "In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival." | ( Chhonker, YS; Do, AV; Ebeid, K; Geary, SM; Leslie, KK; Meng, X; Morris, AS; Murry, DJ; Pham, EL; Salem, AK; Thiel, KW; Wongrakpanich, A, 2018) |
| "In an endometrial cancer xenograft murine model, the tumor size was reduced and animal survival time was increased by co-treatment of Emodin and Cisplatin." | ( Ding, N; Ding, Y; Liu, P; Su, S; Tang, Y; Wang, Q; Yu, X; Zhang, H, 2018) |
| "In a xenograft mouse model of endometrial cancer, concomitant AI administration suppressed the growth of endometrial cancer during ovarian stimulation." | ( Ito, J; Kashiwagi, M; Kashiwazaki, N; Kawahara, T; Nakajima, M; Okamoto, N; Sugishita, Y; Suzuki, N; Takae, S; Uekawa, A, 2018) |
| "The treatment of endometrial cancer (EC) is challenging." | ( de Melo, AC; de Moraes Lino da Silva, F; Fontes Dias, MS; Ingles Garces, ÁH; Moreira, E; Paulino, E; Saramago, M; Thuler, LCS, 2018) |
| "The identification of patients with endometrial cancer (EC) at higher risk for relapse is critical to individualize and better tailor postoperative treatment." | ( Berretta, R; Chiantera, V; Fanfani, F; Frusca, T; Ghezzi, F; Ghizzoni, V; Monterossi, G; Petrillo, M; Scambia, G; Sozzi, G; Uccella, S, 2018) |
| "Although the early-stage endometrial cancer can be effectively managed with surgery, more advanced stages of the disease require multimodality treatment with varying results." | ( Alavanos, A; Andreatos, N; Angelou, A; Antoniou, EA; Apostolou, KG; Athanasiou, A; Damaskos, C; Damaskou, Z; Daskalopoulou, A; Diamantis, E; Dimitroulis, D; Garmpi, A; Garmpis, N; Kalampokas, E; Kalampokas, T; Kontzoglou, K; Kostakis, A; Lavaris, A; Mantas, D; Margonis, GA; Markatos, K; Moschos, MM; Nikiteas, N; Nonni, A; Perrea, D; Sampani, A; Schizas, D; Spartalis, E; Spartalis, M; Tsivelekas, K; Tsourouflis, G; Valsami, S, 2018) |
| "Robotic-assisted surgical staging for endometrial cancer is associated with decreased requirement and expenditure attributable to post-operative pain, post-operative nausea and vomiting, and maintenance and replacement fluid therapy." | ( Agarwal, R; Rajanbabu, A; Unnikrishnan, UG, 2018) |
| "Human Ishikawa endometrial cancer cells were treated with different concentrations of liraglutide." | ( Ayabe, T; Fujii, T; Hiraike, H; Ichinose, T; Kanda, R; Nagasaka, K; Osuga, Y; Ryo, E; Sasajima, Y; Wada-Hiraike, O, 2018) |
| "The majority of endometrial cancers can be cured by surgery alone or in combination with adjuvant chemo- or radiotherapy; however, a subset of patients experience recurrence for reasons that remain unclear." | ( Abrahante, JH; Argenta, P; Bazzaro, M; Chang, Z; Clark, C; Emmings, E; Hellweg, R; Iizuka, Y; Konecny, G; Mooneyham, A; Schütz, F; Shetty, M; Starr, T, 2018) |
| "Ovarian cancer cell lines, as well as endometrial cancer cell lines, were treated with leptomycin B (LMB), cisplatin and TRAIL, either singly or in combination, in order to induce apoptosis." | ( Adam, P; Asselin, E; Demontigny, F; Fabi, F; Joncas, FH; Parent, S; Vincent, K, 2018) |
| "Chemotherapy for advanced or recurrent endometrial cancer requires further development." | ( Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T, 2018) |
| "Enrolled patients had advanced endometrial cancer with measurable lesions and received 2 pretreatment regimens." | ( Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T, 2018) |
| "NEAT1 or LEF1 was overexpressed in endometrial cancer cells while downregulated following post-treatment with progesterone." | ( Deng, Q; He, X; Huang, X; Li, J; Luo, X; Peng, X; Zhong, R, 2019) |
| "We hypothesized that endometrial carcinoma (EC) patients with a prior cancer diagnosis, after accounting for EC arising after tamoxifen-treated prior breast carcinoma, are more likely to have an underlying genetic basis." | ( Brand, A; Buchanan, D; Johnatty, SE; Leung, Y; Oehler, MK; Smith, D; Spurdle, AB; Stewart, CJR; Webb, PM, 2018) |
| "The standard treatment for endometrial cancer is surgery with hysterectomy." | ( Liu, FS; Liu, JC; Yang, HC, 2019) |
| "HEC-1A and KLE, ERα-negative endometrial cancer cells exhibiting high ERRα expression levels, and HEC-1A cell-derived xenograft model mice were treated with XCT790." | ( Kataoka, H; Kitawaki, J; Kokabu, T; Matsushima, H; Mori, T; Tarumi, Y; Yoriki, K, 2019) |
| "For patients with MSI-H recurrent endometrial cancers who have failed first-line chemotherapy, pembrolizumab is cost-effective relative to other single agent drugs." | ( Barrington, DA; Dilley, SE; Smith, HJ; Straughn, JM, 2019) |
| "For early-stage endometrial cancer patients who wish to preserve fertility, progestin treatment is effective." | ( Okazawa, H; Tsujikawa, T; Tsuyoshi, H; Yamada, S; Yoshida, Y, 2019) |
| "RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines were treated with MET and/or SIM." | ( Kim, JS; Rodriguez, GC; Rosales, R; Thaete, LG; Turbov, J, 2019) |
| "Metformin was used to treat endometrial cancer cell lines Ishikawa and RL95-2." | ( Li, F; Li, L; Li, N; Li, T; Liu, M; Qin, X; Xue, J, 2019) |
| "A 71-year-old female with advanced endometrial cancer was treated with pegfilgrastim." | ( Hirata, S; Mokuda, S; Sugiyama, E; Yoshida, Y; Yukawa, K, 2019) |
| "Forty-four endometrial cancer diagnosed patients whose PET/CT scans were performed for treatment planning were included in our study." | ( Erdemoglu, E; Erdogan, M; Evrimler, Ş; Hanedan, C; Şengül, SS, 2019) |
| "Relapse of endometrial cancer following adjuvant chemotherapy often occurs by 1 year after treatment, with common relapse sites of the abdominal cavity and regional lymph nodes." | ( Aoki, D; Arai, M; Mizuno, M; Nakai, H; Nakanishi, T; Nishio, S; Nomura, H; Susumu, N; Takehara, K; Tokunaga, H; Watanabe, Y; Yaegashi, N; Yokoyama, Y, 2019) |
| "Progestin is effective to promote endometrial cancer (EC) cells apoptosis, however, continuous progestin administration causes low level of progestin receptor B (PRB), further resulting in progestin resistance." | ( Cao, W; Gao, W; Sun, X; Wang, L; Zheng, P, 2019) |
| "Thirty-one patients with endometrial cancer (23 with type I, including 17 G1 and six G2 endometrioid adenocarcinomas, and eight with type II, including three G3 endometrioid adenocarcinomas, two carcinosarcomas, and three serous carcinomas) underwent pretreatment FDG-PET/MRI with simultaneous reduced field-of-view diffusion-weighted imaging (DWI)." | ( Chino, Y; Kurokawa, T; Okazawa, H; Shinagawa, A; Tsujikawa, T; Tsuyoshi, H; Yamada, S; Yoshida, Y, 2020) |
| "Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies." | ( Bidzinski, M; Cebotaru, CL; Dutcus, CE; Funahashi, Y; Garcia, AA; Kadowaki, T; Mikheeva, ON; Miller, DS; Penson, RT; Powell, MA; Ren, M; Teneriello, MG; Vergote, I, 2020) |
| "In human Ishikawa endometrial cancer cells, MET treatment (60 μM) decreased cell numbers and elicited distinct temporal changes in ESR1, KLF9, PGR, PGR-B, KLF4, DKK1, and other tumor biomarker mRNA levels." | ( Alhallak, I; Brown, DM; Burnett, AF; Liu, SJ; Montales, MTE; Pabona, JMP; Quick, CM; Rose, T; Siegel, ER; Simmen, FA; Simmen, RC, 2020) |
| "Patients with advanced endometrial carcinoma have limited treatment options." | ( Aghajanian, C; Bratos, R; Brose, MS; Casado Herraez, A; Cohn, AL; DiSimone, C; Dutcus, CE; Makker, V; Messing, M; Mier, J; Oaknin, A; Orlowski, R; Romeo, M; Sachdev, P; Schmidt, EV; Shumaker, R; Stepan, DE; Taylor, MH; Wu, J, 2020) |
| "To compare the Ki-67 index of endometrial cancer cells before and after treatment between the metformin and placebo group in women with endometrial cancer (EC)." | ( Chotikawichean, N; Insin, P; Petchsila, K; Prueksaritanond, N; Yanaranop, M, 2020) |
| "A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy." | ( Asano, H; Ihira, K; Kato, T; Kobayashi, N; Konno, Y; Kudo, M; Mayama, M; Mitamura, T; Nomura, E; Nozaki, A; Takeda, M; Watari, H, 2020) |
| "A total of 57 patients were treated (21 endometrial cancer, 36 complex atypical hyperplasia)." | ( Bodurka, DC; Broaddus, RR; Burzawa, JK; Coleman, RL; Fellman, B; Fleming, ND; Lu, KH; Milbourne, AM; Nick, AM; Pal, N; Ramondetta, LM; Schmeler, KM; Soliman, PT; Sun, CC; Urbauer, DL; Westin, SN; Woodall, ML; Yates, MS; Yuan, Y, 2021) |
| "A retrospective review of patients with endometrial cancer who were diagnosed and treated in Asan Medical Centre from September 2015 to December 2017 was conducted." | ( Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, GW; Nam, JH; Park, JY; Suh, DS, 2021) |
| "Laparoscopy is commonly used for endometrial cancer treatment, and sentinel lymph node (SLN) mapping has become the standard procedure for nodal assessment." | ( Berretta, R; Buono, N; Capasso, I; Capozzi, VA; Chiantera, V; Di Donna, MC; Dinoi, G; Fanfani, F; Giallombardo, V; Monterossi, G; Restaino, S; Scambia, G; Sozzi, G; Uccella, S, 2020) |
| "Main controversies in endometrial cancer treatment include the role of lymphadenectomy and optimal adjuvant treatment." | ( Berg, HF; Bozickovic, O; Engerud, H; Forsse, D; Haldorsen, IS; Halle, MK; Hoivik, EA; Krakstad, C; Trovik, J; Werner, HMJ; Woie, K, 2021) |
| "All consenting endometrial cancer patients receiving primary treatment at Haukeland University Hospital from 2001 to 2019 were included (n = 1308)." | ( Berg, HF; Bozickovic, O; Engerud, H; Forsse, D; Haldorsen, IS; Halle, MK; Hoivik, EA; Krakstad, C; Trovik, J; Werner, HMJ; Woie, K, 2021) |
| "Patients with stage IA grade 2 endometrial carcinoma who asked for fertility-sparing treatment in the Obstetrics and Gynecology Hospital of Fudan University between 2015 and 2017 were enrolled and retrospectively reviewed." | ( Chen, X; Cheng, Y; Luo, X; Lv, Q; Shan, W; Sun, L; Wu, P; Yang, B; Zhang, H; Zhu, Q, 2021) |
| "Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group." | ( Bignotti, E; Boll, D; Bulten, J; Cabrera, S; Eriksson, AGZ; Forsse, D; Galaal, K; Inda, MA; Krakstad, C; Kroep, JR; Lalisang, RI; Lindemann, K; Pijnenborg, JMA; Romano, A; Snijders, MPLM; Sweegers, S; Trum, H; van Beekhuizen, HJ; van de Stolpe, A; van Ginkel, A; van Lonkhuijzen, LRCW; van Weelden, WJ; Weinberger, V; Werner, HMJ; Witteveen, PO; Yigit, R, 2021) |
| "Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases." | ( Bignotti, E; Boll, D; Bulten, J; Cabrera, S; Eriksson, AGZ; Forsse, D; Galaal, K; Inda, MA; Krakstad, C; Kroep, JR; Lalisang, RI; Lindemann, K; Pijnenborg, JMA; Romano, A; Snijders, MPLM; Sweegers, S; Trum, H; van Beekhuizen, HJ; van de Stolpe, A; van Ginkel, A; van Lonkhuijzen, LRCW; van Weelden, WJ; Weinberger, V; Werner, HMJ; Witteveen, PO; Yigit, R, 2021) |
| "Using Ishikawa endometrial cancer cells, we report that E2 treatment exposes a set of progestin-dependent PR binding sites which include both E2 and progestin target genes." | ( Beato, M; Bellora, N; Fernández, E; Fresno, C; Jara, R; La Greca, A; Le Dily, F; Merino, G; Nacht, AS; Quilez Oliete, J; Saragüeta, P; Tarifa Reischle, I; Vallejo, G; Vicent, G; Vidal, E; Villanueva, JL, 2022) |
| "Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear." | ( Baron-Hay, S; Bird, S; Casado Herráez, A; Colomba, E; Colombo, N; Dutta, L; Fujiwara, K; Guerra, EM; Keefe, S; Kim, YM; Lorusso, D; Makker, V; McCormack, MM; Miller, DS; Orlowski, RJ; Pignata, S; Ray-Coquard, I; Sakata, J; Sanli, UA; Santin, AD; Shapira-Frommer, R; Smith, AD; Ushijima, K; Yonemori, K, 2022) |
| "Additionally, the reports representing endometrial carcinoma were assessed for impact on the treatment decision." | ( Bansal, S; Goel, AK; Kapoor, R; Khandelwal, S; Sali, AP; Sancheti, S; Somal, PK, 2022) |
| "Patients with advanced endometrial cancer have a poor prognosis, and treatment options are limited." | ( Boere, IA; Bosse, T; Braak, JPBM; Creutzberg, CL; Kroep, JR; Lalisang, RI; Meershoek-Klein Kranenbarg, E; Ottevanger, PB; Post, CCB; Putter, H; Sonke, GS; Westermann, AM; Witteveen, PO, 2022) |
| "For high-risk endometrial cancer (EC) patients, adjuvant chemotherapy is recommended to improve outcome." | ( Bignotti, E; Bugatti, M; Calza, S; Capoferri, D; Lonardi, S; Odicino, F; Pijnenborg, JMA; Ratti, M; Ravaggi, A; Reijnen, C; Romani, C; Sartori, E; Tognon, G; Zanotti, L, 2022) |
| "Additionally, the treatment of endometrial cancer with compound 968 downregulated the expression of GLS1 and cyclin D1 and upregulated the expression of P21 and E-cadherin." | ( Guo, H; Li, D; Li, W; Liu, N; Pan, G; Sheng, X; Wang, C; Yuan, L, 2023) |
| "We showed that chemotherapy-resistant endometrial cancer cells (ARK1, uterine serous carcinoma and PUC198, grade 3 endometrioid adenocarcinoma) had improved sensitivity and synergy with paclitaxel and carboplatin when treated in combination with AVB-500." | ( Blachut, B; Bruce, SF; Cho, K; Fuh, KC; Hagemann, AR; Khabele, D; Kuroki, LM; Lomonosova, E; McCourt, CK; Mullen, MM; Mutch, DG; Noia, H; Oplt, A; Patti, GJ; Powell, MA; Shriver, LP; Stock, EC; Thaker, PH, 2022) |
| "This study enrolled patients with endometrial cancer who had progressed after platinum-based chemotherapy." | ( Ban, X; Cheng, X; Huang, X; Huang, Y; Li, J; Li, Q; Qiu, Y; Wei, W; Yang, F; Zhang, R; Zheng, M; Zhu, X, 2022) |
| "A total of 119 patients with untreated endometrial cancer underwent FDG PET/computed tomography (CT)." | ( Imajo, M; Ishibashi, M; Kanenishi, K; Mitamura, K; Nishiyama, Y; Norikane, T; Takami, Y; Tanaka, T; Tsuruta, T; Yamamoto, Y, 2022) |
| "Progesterone is used to treat uterine endometrial cancer in young patients wishing to preserve their fertility as well as in advanced or recurrent patients, but its response rate is limited." | ( Aoyama, K; Kataoka, H; Kitawaki, J; Kokabu, T; Mori, T; Tarumi, Y; Yoriki, K, 2022) |
| "In patients with recurrent/advanced endometrial cancer who have progressed after first-line treatment, there are a lack of real-world data on treatment patterns, characteristics, and survival outcomes." | ( Camejo, HS; Heffernan, K; Knott, C; Nikitas, FS; Shukla, U, 2022) |
| "The lack of progress made in endometrial cancer treatment, particularly of high-risk histologic subtypes, disproportionately affects black women who are more likely to be diagnosed with these aggressive tumor types." | ( Cohen, JG; Eakin, CM; Lai, T, 2023) |
| "Metastatic or recurrent endometrial cancers with low survival rate had no standard or limited therapy choice." | ( Chen, JL; Gao, FF; Liu, NF; Sui, XC; Tang, YD; Zhang, TT; Zhang, XL, 2022) |
| "Metastatic or recurrent endometrial cancers with low survival rate had no standard or limited therapy choice." | ( Chen, JL; Gao, FF; Liu, NF; Sui, XC; Tang, YD; Zhang, TT; Zhang, XL, 2022) |
| "Metastatic or recurrent endometrial cancers with low survival rate had no standard or limited therapy choice." | ( Chen, JL; Gao, FF; Liu, NF; Sui, XC; Tang, YD; Zhang, TT; Zhang, XL, 2022) |
| "Human endometrial cancer cell lines Ishikawa and HEC-1A were treated with Pentamidine." | ( Gao, Y; Hu, X; Lin, L; Liu, C; Ouyang, J, 2022) |
| "Human endometrial cancer cell lines Ishikawa and HEC-1A were treated with Pentamidine." | ( Gao, Y; Hu, X; Lin, L; Liu, C; Ouyang, J, 2022) |
| "Human endometrial cancer cell lines Ishikawa and HEC-1A were treated with Pentamidine." | ( Gao, Y; Hu, X; Lin, L; Liu, C; Ouyang, J, 2022) |
| "The majority of patients with endometrial cancer (EC) are diagnosed at an early stage and undergo primary surgery, followed by observation or adjuvant therapy according to risk factors on surgical samples." | ( Caretto, M; Coccia, N; Fuentes, T; Gadducci, A; Laliscia, C; Mattioni, R; Morganti, R; Paiar, F; Perrone, F; Pistolesi, S; Puccini, P, 2023) |
| "The present study shows that ET after endometrial cancer surgery may be underused, even in women who underwent surgery between 40 and 44 years of age and without adjuvant therapy." | ( Egawa, M; Hamanishi, J; Inayama, Y; Kawakami, K; Mandai, M; Mizuno, K; Takeuchi, M; Yamaguchi, K, 2023) |
| "In patient-derived primary human endometrial carcinoma cells and established lines, treatment with IMT1 potently inhibited cell viability, proliferation, cell-cycle progression and motility, while inducing robust caspase-apoptosis activation." | ( Chen, YG; Li, SP; Ou, L; Shen, FR; Zhang, Y, 2023) |
| "Worse prognosis of endometrial cancers (EC) in tamoxifen-treated women compared to non-tamoxifen-treated women been proposed." | ( Akbari, A; Akbari, ME; Amin Amlashi, M; Ardehali, SH; Barragan-Carrillo, R; Chavarri-Guerra, Y; Ghanavati, M; Javid, Z; Khorshidi, Y; Rahmani, J; Shadnoush, M, 2023) |
| "Advanced and recurrent endometrial carcinoma remains a difficult diagnosis to treat due to the limited and ineffective available treatment options following platinum and taxane chemotherapy." | ( Miller, DS; Spirtos, AN; Walker, CA, 2023) |
| "Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin." | ( Aghajanian, C; Al Baghdadi, T; Backes, F; Beffa, L; Cantuaria, GH; Eskander, RN; Fader, AN; Gien, LT; Girda, E; Hill, EK; Hinchcliff, EM; Hope, JM; John, VS; Kavecansky, J; Landrum, LM; Leath, CA; Lele, SB; Mannel, R; Mathews, C; Moore, RG; Musa, FB; O'Cearbhaill, RE; Powell, MA; Shahin, MS; Sill, MW; Thaker, PH; Welch, S, 2023) |
| "In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone." | ( Aghajanian, C; Al Baghdadi, T; Backes, F; Beffa, L; Cantuaria, GH; Eskander, RN; Fader, AN; Gien, LT; Girda, E; Hill, EK; Hinchcliff, EM; Hope, JM; John, VS; Kavecansky, J; Landrum, LM; Leath, CA; Lele, SB; Mannel, R; Mathews, C; Moore, RG; Musa, FB; O'Cearbhaill, RE; Powell, MA; Shahin, MS; Sill, MW; Thaker, PH; Welch, S, 2023) |
| "However, the role of ferroptosis in endometrial cancer treatment remains to be discussed." | ( Hayashi, M; Murakami, H; Ohmichi, M; Terada, S, 2023) |
| "Although many patients with endometrial cancer (EC) or atypical endometrial hyperplasia (AEH) achieve complete remission (CR) after high-dose medroxyprogesterone acetate (MPA) treatment, no consensus has been reached on management after CR." | ( Eguchi, S; Ga, H; Honjoh, H; Miyamoto, Y; Mori, M; Nishijima, A; Osuga, Y; Sone, K; Taguchi, A, 2023) |
| "No cases of endometrial carcinoma or hyperplasia were observed in ospemifene trials, nor polyps with atypical hyperplasia or cancer after up to 52 weeks of treatment." | ( Beauchemin, C; Black, D; Castonguay, A; Ferenczy, A; Marouf, R; Royer, C; Simon, JA, 2023) |